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Abstract 
Chronic lymphocytic leukaemia (CLL) is a common type of leukaemia and it is 
frequently diagnosed in Western countries. Current therapy to cure this frequently 
diagnosed leukaemia is unsatisfactory. Therefore, the search for potential drugs has 
become an important research topic in recent years. 
Parthenolide, an active component from the plant Feverfew, is a sesquiterpene lactone 
which includes an α-methylene-γ-butyrolactone moiety. Parthenolide (PTL) displays a 
variety of biological activities in drug studies while exhibiting good anti-leukaemic 
activity against primary AML cells in vitro. The poor aqueous solubility and non-
selective reactivity of PTL are two major issues that limit its clinical study as a 
potential drug. Therefore, a series of PTL derivatives have been synthesised through a 
Michael addition reaction in this project and try to conquer these problems.  
The biologically active component, parthenolide, was extracted, isolated and purified 
from a few different types of medicinal herb Feverfew by recombining extraction 
procedures developed in this project. Before commencing the study of PTL, the α-
methylene-γ-butyrolactone, tulipane, will be studied as a model substrate to test both 
the derivatisation chemistry and the biological screens prior to using the more 
precious parthenolide.  
All derivatives have been preliminarily tested by Lipinski rules; they passed the tests 
and proved almost all the compounds are increasing the water solubility by estimated 
the LogP values used three different ways.  
Eight PTL derivatives have been evaluated for their anti-cancer activity. Five 
compounds, 14a-d and 14f, showed similar anti-cancer activity against CLL cell lines 
in vitro compared with parent compound, with LD50 values in a range of 5-10 µM. 
The five active compounds have been taken forward to further in vitro and in vivo 
studies. Also, in future biological work, 10 unexamined remaining PTL derivatives 
(15a-g) should also be tested against CLL cell lines. Therefore, a structure-activity 
relationship will be able to be probed and developed. 
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Chapter 1: Introduction and Literature Review 
1.1 Introduction 
Parthenolide (PTL) is a sesquiterpene lactone which includes an α-methylene-γ-
butyrolactone moiety. It displays a variety of biological activities in drug studies, 
including anti-carcinogenic and anti-inflammatory properties. This biologically active 
component was extracted, isolated, and purified from three different types of the 
medicinal herb feverfew in this project.
1,2
 
This report presents the progresses on the researches of both literature and lab works 
about parthenolide derivatives as potential leukaemia drugs. After the first step of 
extracting PTL from feverfew, the next stage is the design and synthesis of PTL 
derivatives. Within this stage, various types of amines have been used to modify the 
core biological active structure of PTL to undergo a Michael addition reaction. 
Then this report will conclude with advanced biological findings of synthesised 
derivatives. The aim of this stage is to examine the anti-cancer activity of PTL and 
derivatives in three different types of chronic lymphocytic leukaemia (CLL) cell lines 
in vitro. Hence, amino derivatives (14a–d and 14f) with similar anti-cancer activity to 
the parent compound PTL will be reported at the end of this stage of research. 
 
1.2 Aims of the Report 
The main objective of this report is to build comprehensive knowledge in the area of 
the organic synthesis and medicinal chemistry of the sesquiterpene lactone 
(parthenolide). To achieve the main objective, there are some subsequent aims of this 
report: 
1. Through isolating PTL from feverfew by recombining procedures developed in 
this project to improve isolation time, cost efficiency and obtain a good yield; to 
find out the best type of plant and the best harvest season for the plant containing 
the maximum amounts of PTL. 
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2. To find out the drug-like properties of PTL by modifying the α,β-unsaturated ester 
part of the molecule through Michael-like addition reactions. 
3. To find out whether α-methylene-γ-butyrolactone (tulipane) is a suitable model 
for pre-screening prior to parthenolide modifications; and identify any possible 
relationships between PTL and tulipane derivatives. 
4. Through examining anti-cancer activity of all derivatives against CLL cell lines, 
find out whether any derivative has better solubility than PTL whilst retaining the 
same activity in cell-based assays. 
The following actions have been taken to achieve the above-mentioned aims. First of 
all, this project begins from extraction, isolation and purification of parthenolide (PTL) 
from the medicinal herb feverfew. Then it moves onto its development in organic 
synthesis. Various types of amines were used to modify the core biological active 
structure of PTL to undergo a Michael addition reaction to improve the aqueous 
solubility and retained the biological activity. Also, due to tulipane (6), the α-
methylene-γ-butyrolactone was studied as a model substrate to both test the 
derivatisation chemistry and the biological screens prior to using the more precious 
parthenolide. 
An advanced stage of biological studies of PTL derivatives was treatment in three 
different types of CLL cell lines in vitro to examine their anti-cancer activity. 
Therefore, the primary objective of this project is to build comprehensive knowledge 
in the area of the organic synthesis of the sesquiterpene lactone (parthenolide) and 
application in medicinal chemistry can be established. 
 
1.3 Cancer 
Normally, the division and proliferation mechanisms of trillions of living cells in our 
body are controllable. If cells start to divide uncontrollably they may become 
cancerous.
3
 Cells become cancerous because the DNA is damaged during cell division, 
which may inhibit the normal actions of these cells. Cells containing damaged DNA 
either repair the damage or die; however, if the damaged DNA persists and the cell 
survives, cell proliferation could lead to cancerous mutations and contribute to 
tumourigenesis.
3-5  
Confidential copy for assessment 
© University of Birmingham 2013 
9 
The vast majority of cases show that cancer cells form a tumour, and there are only a 
few cancers, e.g. leukaemia, which do not form tumours. In contrast, this kind of 




1.4 Chronic Lymphocytic Leukaemia (CLL) 
 
Figure 1: B-cell chronic lymphocytic leukaemia.7 
The most frequently diagnosed leukaemic, chronic lymphocytic leukaemia (CLL), is a 
B-lymphocyte proliferative disease within the hematopoietic system. The 
hematopoietic system supplies all cellular blood components and forms new blood 
cells daily in the human body. CLL is cancer of the abnormal lymphocytes (a kind of 
white blood cells) that can be diagnosed from inspection of peripheral blood, bone 
marrow, the liver, the spleen, and lymph nodes where small round lymphoid 
aggregates are observed (Figure 1).
8,9 
This type of leukaemia is very common in Western countries.
9 
The incidence rate is 
6.15 in 10 million people, accounting for about 25% of all cases of leukaemia. CLL in 
Asian countries is relatively rare;
 
the ratio does not exceed 5% of all cases of 
leukaemia in Japan, China and India.
8,9
 CLL can occur in people at any age, but is 
most prevalent in people over the age of 60. The age of onset has a mean value of 65, 
where incidence increases with age and a higher proportion of males than females are 
affected, showing a ratio of approximately 2:1.
3,8-10  
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So far, there is still no definite explanation for the causes and pathogenesis of CLL. 
CLL is most likely to be caused by both internal and external factors. For example, 
family history will be a major internal risk factor for CLL, while chemical substances, 
such as formaldehyde and benzene, will be a clear case of which an external factor 




There are no standard curative programs. The only treatment available remains 
palliative care. Patients with early diagnosis or stable conditions may not require the 
use of anti-tumour therapies, because these treatments do not generally prolong 
patient survival.
9-12
 Also, cancer therapies such as oral alkylating agents will likely 
shorten the period of the patient's life rather than extend it.
8,9,11,12
 
Overall, the recent CLL treatment programme mainly uses a single agent or 
combination of chemotherapy in late-stage patients, depending on the severity of the 
patient's symptoms and the degree of tolerance to chemotherapy which is dependent 
on age or comorbidities.
8,10,11
 Therefore, there is an unmet need for less genotoxic or 
cytotoxic therapies for the management of this disease. 
 
1.5 Feverfew 
Feverfew (Tanacetum parthenium L.) (Asteraceae) is a medicinal plant which is 




Figure 2: Tanacetum parthenium (feverfew) 
From medicinal herbs such as feverfew, a variety of medicinal components can be 
extracted.
13
 One of these components is parthenolide. Parthenolide (PTL) has shown 
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activity against a few tumour cells in vitro, inhibiting the proliferation of colon cancer, 
liver cancer, cholangiocarcinoma, acute and chronic leukaemia, multiple myeloma 




Figure 3: Structure of Parthenolide 
 
1.5.1 Extraction of Parthenolide 
In recent years, there have been a variety of extraction procedures of parthenolide 
reported. There are three main differences between the extraction solvent system, 
extraction procedures and analysis methods used.
16-18
 Yoshioka et al. chose 
chloroform or petroleum ether as the solvent to extract sesquiterpene lactones, 
especially PTL, and identified it with NMR spectroscopy.
19
 Marchand et al. also used 
chloroform as a solvent, but a high-performance liquid chromatographic (HPLC) 
analysis method was first used to identify PTL.
17,19
 Two different extraction methods 
have been published at almost the same time: Groenewegen et al. used a chloroform 
stirring extraction method, and the petroleum ether Soxhlet extraction procedure were 
reported by Awang et al..
16
 In the more recent publications, more solvents, such as 
acetone, acetonitrile, methanol, and organic/aqueous solvent systems were tested; and 




Only a few researches focused on the solvent effect of the extraction procedure. Zhou 
et al. examined different solvents on same amounts of feverfew with both stirring and 
Soxhlet extraction. The extraction results showed the highest percentage of PTL was 
extracted by the stirring method with acetonitrile and water mixture (90:10; v/v. 
0.32%); ethanol, acetone and chloroform showed similar extraction capabilities 
(between 0.26% to 0.28%). However, petroleum ether showed a lower percentage of 
PTL (0.16%) and proved that it is not a good solvent system for extraction.
19
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When the solvent system is mixed with different amounts of water respectively, 
excellent results have been shown; for example, in ethanol with 10% water, 
acetonitrile with 10% water, and acetone with 20%, 30% water, higher than 0.3% of 
PTL was always extracted.
19
 As water plays an important role in extraction process, a 
conclusion can be drawn: the reason for water’s important role in extraction process is 
that the aqueous phase will attract the hydrophilic components of feverfew and lead to 
the PTL dissolving more easily into the organic phase. 
Zhou’s group also reported that Soxhlet extraction using ethanol, acetonitrile, acetone, 
chloroform, and petroleum ether, which is based on the order of decreasing solvent 
polarity, was adopted and the results of the percentage of PTL showed a steady 
decreased from ethanol to petroleum ether (0.31%, 0.3%, 0.28%, 0.27% and 0.12%). 
By a more polar solvent system, the efficiency of extract PTL appeared to be better, 
and a polar compound can better dissolve in a polar solvent system. But the nonpolar 
solvent petroleum ether is not a good solvent to extract PTL from feverfew, and has 
shown significantly poor efficiency.
19
 
Therefore, stirring extraction showed a better efficiency than Soxhlet, as stirring 
extraction only takes a short time and room temperature, comparing to Soxhlet 
extraction which requires reflux for 24 hours. In addition, for the stirring extraction 
method, the maximum amount of PTL was extracted from feverfew within 10 minutes 
in the acetonitrile and water solvent system (see Figure 4).
19
 
Furthermore, Marete et al. reported that PTL could be extracted into water and with 
the increase in temperature through an aqueous stirring extraction, the content of PTL 
and a number of phenolic compounds increased; also the maximum concentration of 
PTL was obtained at 75–80°C as observed by extracts (see Figure 5). A higher 
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Figure 4: Maximum amount of PTL can be extracted after 10 minutes using the bottle stirring 




Figure 5: Feverfew samples extracted in water at different temperatures. 20 (Permission to use from copyright of 
Elsevier Ltd, 2009) 
 
1.5.2 Origin and Composition of PTL 
Feverfew is generally grown in Europe and North America.
18,21
 Some studies have 
suggested that PTL was only found in Europe– and United States–grown feverfew, 
not in Mexican or Yugoslavian.
18
 Also Awang et al. reported that the percentage of 
PTL varies in different parts of feverfew (Table 1)
18
. 
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Table 1: Content of Parthenolide extracts by HPLC and NMR spectroscopy procedures.18  






Leaf 0.83 0.85 
2 Seed 1.52 1.82 
3 USA 
 
Mixed leaf and flowering top 0.18 0.21 
4 Leaf 0.09 0.13 
5 Flowering top 0.27 0.35 
6 Canada 
 
Leaf, (pre-flowering) 0.33 0.64 
7 Leaf (post-flowering) 1.27 1.62 
8 Flowering top 0.46 1.01 
A conclusion can be drawn from the data presented in Table 1 that seeds contain 
much more PTL than the other parts of feverfew such as the leaf. Extraction of seed 
(entry 2) is twice rich in PTL than leaf (entry 1), as well as entry 7 (mixture of leaf 
and seeds), has shown much higher yield obtained than leaf or flower only (entry 6 
and entry 8, respectively). European feverfew is currently confirmed to contain the 
highest percentage of PTL (entry 1), whereas feverfew originating from the USA 
contains much lower percentages yield (entry 3 to entry 5). 
 
1.6 Parthenolide 
Parthenolide can be extracted from the medicinal herb feverfew. In the last few years, 
PTL has shown exceptional anti-cancer and anti-inflammatory properties in drug 
studies and development.
1,2,22 
However, the poor aqueous solubility of PTL has 
limited its clinical study as a potential drug. Another problem presented is that of the 
reactivity of PTL. PTL, as a good Michael acceptor, can be bound with many 
intracellular thiol groups in vitro due to the loss of biological activity in vain. 
Therefore, many research groups have hypothesised a new pro-drug approach to 
conquer these problems. 
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Scheme 1: Palladium-catalysed arylation of PTL.23  
To understand the reactivity of α-methylene-γ-butyrolactone moiety of PTL, Han et al. 
reported a palladium-catalysed arylation reaction of PTL to afford 2 (Scheme 1). 
They used a series of aryl iodides undergoes in a Heck reaction and only a single exo-
cyclic olefin product (E-olefin geometry) was detected. Derivatives that contained an 
electron-withdrawing substituent at meta or para position have shown good activity 
against HeLa cells.
23
 Also, Hwang and co-workers modified PTL by reducing the 
enone olefin of α-methylene-γ-butyrolactone functional group to afford compound 3 
(Scheme 2).
24
 However, this compound has showed no anti-leukemic activity against 




Scheme 2: The enone olefin of PTL has been reduced by palladium.24  
A recent study has suggested that the epoxide moiety of PTL may affect its structural 
stability and this is a possible reason why PTL has a short half-life in mouse plasma 
(only 0.34 hours).
26
 Jing Long et al. reported a cyclopropyl analogue (4e) that 
replaces the epoxide moiety with a cyclopropyl group in three steps from 4a 
(Costunolide) in September 2013. The new analogue has shown a longer half-life in 
mouse plasma (13.9 hours) compared with the parent compound (only 0.34 hours). 
This PTL derivative has been confirmed that it has a significantly more stable 
structure than PTL. Also this compound has shown similar biological activities 
compared with PTL. This may suggest that the epoxide functional group is unlikely to 
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Scheme 3: A novel cyclopropyl analogue of PTL was synthesised in a three-step reaction by Jing Long et al.. 
Conditions: A) DIBAL, toluene, RT, 4 hours; B) Ti(O-i-Pr)4, D-(-)-DIPT, TBHP, CH2Cl2, -20 ℃, 20 hours; C) 
TEMPO, PhI(OAc)2, CH2Cl2, RT, 10 hours; D) Et2Zn, CH2I2, CH2Cl2, -10 ℃, 1 hour.
26 
The Michael addition reaction of nucleophiles to electron-deficient α,β-unsaturated 
lactones is one of the most valuable organic synthesis reactions to form a new C-C 
bond or C-N bond. It is also frequently used to synthesise natural products or drugs. 
The most important part of this class of reaction is the creation of a new C-N bond 
resulting in products that contain β-amino ester functionality. This C-N bond is a 
polar bond in which the nitrogen atom has more electronegativity than oxygen. As a 
result, the structure that contains a C-N bond is more soluble in water. Amines are 
good nucleophiles and the lone pair of nitrogen atoms will always attack an 
electrophile in the Michael addition mechanism. Also, some amine derivatives often 
have biological activities and are useful intermediates in organic chemistry.
22,24
 In 
addition, some aminoparthenolide derivatives have been synthesised in a one-step 
process by Neelakantan et al..
25
 This is a thermodynamically controlled process under 
the standard conditions of the addition reaction (Scheme 4). When an amine attacks 
an α,β-unsaturated lactone moiety, the protonation of intermediate enolate is exo 
selective. The reason is that the intermediate enolate from conjugate addition on the 
endo face undergoes a 1,3-diaxial interaction of hydrogen on C-6, axial hydrogen on 
C-8 and two hydrogen on C-13. This means only the (R) configuration is displayed at 
carbon 11 in the Michael-type addition of amines to parthenolide (Figure 6)
24,26
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Scheme 4: Michael addition of PTL.27 
 
Figure 6: Structure of Parthenolide and Structure of exo and endo face protonation product25,27 
 
In the past few years, Nasim’s research group has reported that a series of 
parthenolide analogues have been synthesised and demonstrated that PTL derivatives 
have more water-solubility than parent compound. This result would have direct 
impact on their ability to become potential drugs because better solubility in water can 
increase the bioavailability.
27
 The aminoparthenolide analogues have not only 
improved drugability and bioavailability, but also kept the anti-leukemic activity in 
vitro and in vivo.
21-25 
To better understand the structure activity relationship of PTL 
and amino derivatives, Neelakantan et al. used a series of primary and secondary 
amines with PTL utilising a Michael-type addition to synthesise aminoparthenolide 
derivatives, such as DMAPT or LC-1 (compound 5a), which has higher 
bioavailability and similar durability (Scheme 4).
27
 Compounds 5a-j were tested for 
their anti-cancer properties on acute myeloid leukaemia (AML) and the results 
showed that amine derivatives can maintain the biological activity of PTL after 
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1 1   84 1.4 
2 5a
A Methyl Methyl 93 1.7 
3 5b Methyl Ethyl 80 2.5 
4 5c Methyl Propyl 95 3.2 
5 5d Methyl Butyl 68 2.8 
6 5e Methyl Pentyl 46 4.6 
7 5f Methyl N-2-Hydroxyethyl 86 1.8 
A: This compound is DMAPT B: LD50 (Median Lethal does) a commonly indicator that used for description of 
toxic substances or radiation toxicity 
The anti-cancer activity of those aminoparthenolide derivatives against primary AML 
cancer cells in vitro has been shown in Table 2. PTL (entry 1) has obtained 84% cell 
death against primary AML cells. Derivative 5a-c (entries 2-4) and 5f (entry 7) 
showed significant levels of killing in primary AML cells (80–93% cell death); 
especially 5a, 5b, 5c and 5f showed a higher anti-leukaemic activity than the parent 
compound. Derivative 5c (entry 4) and 5e (entry 6) showed loss of the anti-leukaemic 
activity and displayed relatively higher LD50 values comparing with other derivatives 
against primary AML cells (2.8 µM and 3.2 µM respectively). 
Dimethylaminoparthenolide (DMAPT, 5a, entry 2) is one of the best 
aminoparthenolide derivatives as it causes 93% cell death at 10 µM probe assay when 
the LD50 value is 1.7 µM. On the other hand, DMAPT has an aqueous solubility, 




Finally, in recent years, some fluorinated aminoparthenolides were designed and 
synthesised by Woods et al..
28
 They reported that a reversible Michael addition 
process can happen with in vitro tests at the presence of glutathione (cellular 
antioxidant) and with further derivatives be degraded to free PTL and amines (Figure 
7).  
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Figure 7: 19F NMR spectroscopy showed prodrug convert back to SM.22,28 (Permission to use from copyright of 
American Chemical Society, 2011) 
As illustrated in Figure 7, PTL derivative can eliminate amine in the presence of 
biological thiol (glutathione) more easily and 
19
F NMR data shows that the 
concentration of 4-trifluoromethylpiperidine is almost converted back from PTL 
derivative. Furthermore, the data gave a hint that free PTL would be preferentially 
trapped by a Michael addition of glutathione rather than recombining with 4-
trifluoromethylpiperidine. On the other hand, it can be easier to understand the 
biological studies of PTL and derivatives under the reversible reaction in vitro or in 
vivo. The biological activity of PTL has been found to be related to the nucleophilic 
reaction of the α-methylene-γ-lactone ring (as the Michael acceptor) with intracellular 
thiol groups like glutathione. During the familiar Michael addition reaction of PTL 
and glutathione, a variety of targets will be activated or inhibited, thereby acting as a 
biological switch for signalling downstream events (biological study of PTL and 
glutathione will be outlined in detail in chapter 1.7).  
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Scheme 5: Michael addition reaction of Tulipane and PTL 
The α-methylene-γ-butyrolactone (6) has a similar structural relationship to 
sesquiterpene lactones PTL (1) and additionally is a good Michael acceptor. 
Conjugate addition mechanisms of both tulipane (6) and parthenolide (1) are shown in 
Scheme 5. Amines are good nucleophiles. The non-bonding pair of electrons of 
nitrogen atom will readily attack the electrophile double bond of tulipane in the 
Michael addition reaction as same as PTL. 
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The only difference is that a single (R) stereocentre is obtained at C-13 for Michael 
addition reactions of parthenolide with amines. Stereoselectivity is observed to a 
selective exo face protonation of the enolate intermediate due to the steric effects of 
the substrate outline in Figure 6. 
Therefore, due to the similar reactivity of tulipane with parthenolide and the ease of 
access to this readily available inexpensive lactone, tulipane can be considered a 
suitable pre-screening substrate prior to parthenolide modifications. 
Overall, the Michael addition reaction is frequently used to synthesis natural products 
or drugs. The most important part of this class of reaction is the creation of a new C-N 
bond and the C-N polar bond of compound could be shown more soluble in water. As 
in previous study, Hewaman et al. and Neelakantan et al. have successfully 
synthesised a series of aminoparthenolide analogues undergoes Michael addition 
reaction. Some amino derivatives obtained promising results in vitro against acute 
myeloid leukaemia (AML) and the implication of these previous studies are that it 
could be a logical step to treatment aminoparthenolide derivative on CLL. Therefore, 
this MSc research project has used the simple and highly efficient method for the 
synthesis of β-amino carbonyl compounds from aliphatic, aromatic, and heterocyclic 
amines and α,β-unsaturated Michael acceptors under catalyst free conditions. 
 
1.7 Biological Activity of Parthenolide 
The α-methylene-γ-butyrolactone functionality appears to be at the centre of most of 
the biological activities connected with feverfew. The α-methylene-γ-butyrolactone 
moiety of PTL plays an important role for biological activities when one considers the 
exceptional ability of this functionality to act as a Michael acceptor in biological 
systems. A conjugate addition reaction presents in vitro or in vivo, the nucleophile 
very often appears as a thiol group and this result was firstly confirmed by Kupchan's 
group.
29
 Recently published reports have shown that PTL displays anti-leukaemic 
activity and data suggests that its effects involve the induction of oxidative stress and 
inhibition of NF-κB signalling.
30
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1.7.1 Redox homeostasis 
 
Figure 8: Part A) The balance between reactive oxygen species (ROS) and antioxidants (AO). Part B) Either 
increased reactive oxygen species or reduced antioxidants will disrupt redox homeostasis and eventually lead to 
cell death. 
Redox homeostasis can be defined as the way to maintain a constant redox state 




Oxidative stress results from either enhanced intracellular ROS production or 
decreased cellular antioxidant defences. In addition, the level of oxidative stress in 
normal cells and tumour cells are different, with tumour cells having an especially 
higher level of oxidative stress.
15,32
 This means that tumour cells may be more 
susceptible to therapies that induce more oxidative stress. 
An imbalance of redox homeostasis leads to oxidative stress results in oxidative 
damage to cellular components such as DNA and protein. This can induce 
downstream cellular events that eventually lead to cell death (Figure 8: Part B).
33,34
 
An important and abundant cellular antioxidant is glutathione. 
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Figure 9: Structure of Glutathione 
Glutathione, an endogenous tripeptide (Figure 9), exists in two different forms: one is 




Figure 10: The Glutathione system.34 
Glutathione converts to a reactive species which donates an electron to ROS (H2O2 in 
Figure 10) and reacts with another reactive glutathione rapidly to form GSSG. GSH 
is regenerated from GSSG using the enzymatic activity of glutathione reductase (GSR) 
and the NADPH cofactor. (Figure 10).
34
 
In general, most glutathione exists in a reduced state of GSH, while less than 10% of 
glutathione exists as GSSG. The rising volume of GSSG regenerating to GSH can 
increase the oxidative stress. Indeed, Glutathione (GSH) and other protein thiol 
groups play an important role in cell survival. Many studies have shown that 
disrupting the accurate redox state by depleting GSH or other intracellular thiol 
groups will induce downstream cellular events that eventually lead to cell death.
34
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One of the ways that PTL is thought to induce oxidative stress is by reacting with 
glutathione, thereby reducing the levels of this antioxidant and exposing the cell to 




Sen et al. discovered nucleoprotein factors to enhance the combination of sub B locus 
and immunoglobulin K light chain genes from the nuclear extracts of B lymphocytes, 
so that the transcription of the K light chain can be regulated. Such a nuclear 
transcription factor was named κB.
35
  
NF-κB plays an important role in the survival and proliferation of normal and 
neoplastic B cells. In CLL, NF-κB has been found to be activated to a variable degree, 
regardless of disease stage or treatment status. NF-κB is vital for the regulation of 
many genes that prolong cell survival time and for the regulation of many processes in 
the development of cancer, including clonal expansion, growth, differentiation, 
angiogenesis, adhesion, and extracellular matrix degradation. Therefore, NF-κB has 
been suggested to be a promising target for therapy in CLL.
36-41
 
1.7.2.1 Parthenolide inhibits NF-κB 
NF-κB is sequestered in the cytoplasm in a non-activated form by complexing with 
the inhibitory protein, IκB. Phosphorylation of IκB by IκB kinase (IKK) results in the 
proteosomal degradation of IκB and the translocation of NF-κB into the nucleus 
where it can transactivate gene expression. NF-κB and IκB-α are involved jointly in 




In vitro studies have shown that parthenolide inhibits the activity of NF-κB. PTL 
directly binds and inhibits IKK (IκB kinase), blocking the phosphorylation and 
degradation of IκB, The result is inhibition of NF-kB activity through stabilisation of 
IκB.
18,40-44
 Consequently, PTL and its derivatives use IκB phosphorylation as drug 
targets to inhibit NF-κB, Figure 11.
40,41 
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Figure 11: Left side: Basic mechanism of NF-κB action. Right side: 1) Activation of IKK. 2) Phosphorylation of 
IκB-α and degradation of IκB to induce the activation of NF-κB. 3) Release NF-κB into nucleus. 4) NF-κB to bind 
with DNA. Right side: Basic pathway of parthenolide mediated anti-cancer and anti-inflammatory activities: 1) 
PTL inhibition of IKK. 2) Inhibition of phosphorylation of IκB-α and degradation of IκB to induce the activation 
of NF-κB. 3) Inhibition of NF-κB mediated gene transcription.16,40,41 
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Chapter 2: Results and Discussions 
There are two factors, origin and composition, that affect the amount of parthenolide 
(PTL) in feverfew. Several different types of feverfew were cultivated and then tested 
for the maximum content of PTL in this project. Around one hundred samples of three 
different types of seeds, golden feverfew, feverfew and tansy, were tested; all of them 
were cultivated by Winterbourne Botanical Garden at the University of Birmingham. 
Plants were all grown in greenhouses in winter 2012 to avoid the influence of 
fluctuating seasonal conditions. 
 
2.1 Extraction of the PTL using Developed Extraction 
Procedure 
Some literature reports suggested to use different extraction procedures as discussed 
in chapter 1.5.1. A recent report indicates the possibility of extracting PTL into water 
with HPLC (High Performance Liquid Chromatography) procedure to purify and 
isolate PTL.
20 
However, HPLC is a time-consuming and expensive method and may 
not be appropriate for extraction of large quantities. So if a non-HPLC method can be 
developed in this project to improve isolation time, cost efficiency and obtain a good 
yield, it is a better method. 
 
In order to use simplified purification methods such as column chromatography and 
recrystallisation, an effective extraction was required and only contains the minimal 
number of components. As mentioned before, PTL has shown lower water solubility, 
but it can be seen as an advantage if the water extraction procedure is applied. 
Because water will absorb all the hydrophilic compounds, PTL is more easily 
extracted by an organic solvent. Therefore, after the crude aqueous solution extraction, 
PTL can be extracted with a further organic solvent (e.g. chloroform) extraction from 
the water extracts. In fact, a recombining extraction and purification procedure was 
developed by Fossey’s group in which a minimum number of components were 
extracted after the whole extraction procedure, compared to previous methods. Their 
purification method only uses traditional purification procedures such as column 
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chromatography and recrystallization, which is removing the HPLC procedure to 
obtain the pure target product (PTL). 
 
2.2 Results from Extraction of Different Plants 
Only fresh plant matter was used in this project and the plants were not dried before 
extraction. The extraction yields in this project and the yields from literature are not 
comparable because they used dried plants. Fresh golden feverfew, feverfew and 
tansy were extracted by this novel extraction procedure. The amount of extracted of 
PTL was shown in Table 3. 
Table 3: Plants were extracted by novel procedure 





Crude extract of 
PTL  
Amount of PTL  




1 Fresh golden 
feverfew 
844 g 5 g 1.3 g 0.15 
2 Fresh feverfew 798 g 3 g 0.1 g 0.01 
3 Fresh tansy 
(flowering) 
2.56 kg 6 g 1.4 g 0.05 
4 Fresh tansy 
(seeds) 
2.242 kg 8 g 2.9 g 0.13 
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Figure 12: The different periods of tansy 
When comparing entry 1 and 2 in Table 3, the obtained yield of PTL from golden 
feverfew is fifteen times more than feverfew when using similar weight of plant 
matter. Entries 3 and 4 are both extraction of tansy; the yield of PTL for tansy is also 
less than golden feverfew. However, when extracting similar amounts of tansy matter 
(Entries 3 and 4 in Table 3), Tansy matter containing seeds has threefold more 
parthenolide compared to the flowering plant. Consequently, the results may indicate 
the relative concentrations of PTL in different species type. Golden feverfew was the 
best plant containing the maximum amount of PTL. Also, this result confirms seeds 
contain much more PTL than the other parts of feverfew. 
PTL was fully characterised by melting point, mass spectrometry, proton NMR, 
carbon NMR and IR. As the formation of PTL is colourless crystal, it has also 
confirmed by single crystal X-ray analysis (Figure 13). The absolute structure of PTL 
has been shown in Figure 14 and it indicated the same stereochemical features 
compared with literature structure.
45
 
This period of time is the time of 
flowering 
Plants contain seeds and are 
starting to dry in this period 
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Figure 13: Single crystal structure of PTL 
 
Figure 14: The absolute structure of PTL 
 
2.3 Tulipane (6) Modification 
 
 
Figure 15: Tulipane has a similar structural relationship to PTL. 
Tulipane (6), α-methylene-γ-butyrolactone, has a similar structural relationship with 
PTL. It is a good Michael acceptor and it shows similar reactivity to PTL in organic 
chemistry. Both Michael addition mechanisms of PTL and tulipane were given in 
Scheme 5 and they were proceeded via the conjugate addition to the exocyclic double 
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bond on the α,β-unsaturated lactone. In addition, tulipane is a simple, readily available 
chemical reagent with a lower price than PTL. 
Due to the similar reactivity of tulipane with PTL and the ease of access to this readily 
available inexpensive lactone, tulipane was used as a model substrate to test both 
derivatisation chemistry and the biological screens prior to using the more precious 
parthenolide. Therefore, the simply and highly efficient method of Michael addition 
reaction was used to synthesis β-amino carbonyl compounds from aliphatic, aromatic, 
heterocyclic amines and α,β-unsaturated Michael acceptors (PTL and tulipane) under 
catalyst-free conditions. 














Hydrogen Prop-1-yne 60 
2 6b 
 
Hydrogen Benzyl 61 
Primary amines were attempted first in this project. Two tulipane derivatives were 
obtained from the Michael reaction of primary amines with tulipane. Propargylamine, 
a primary alkyne amine, contains a carbon-carbon triple bond. One advantage of 
propargylamine is that it can be used as an intermediate to increase the diversity of its 
derivative undergoing ‘click chemistry’ in future, such as to introduce a triazole 
derivative. Propargylamine was reacted with α,β-unsaturated lactone into a stirred 
methanol solution at room temperature for 24 hours. Reaction progress was monitored 
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by Thin-layer chromatography (TLC) and target product 6a was isolated using the 
general experimental procedure (Method A can be found in experimental section).  
Target compound 6b was synthesised using benzylamine, a primary aromatic amine, 
as the starting marital reacted with tulipane through the general procedure A. Both 
primary amine derivatives 6a and 6b have shown similar reaction yields, 60 % and 
61 % respectively. For target compound 6b and 9e (Table 7, entry 5), both contain 
aromatic groups, and the different number of aromatic groups may give rise to 
different biological results.  
However, previous work by Fossey’s group suggests that when reactions used excess 
amounts of primary amines, they caused a major by-product. These reactions have 
undergone the 1,4-conjugate addition firstly, then were followed with a 1,2-addition 
of excess primary amine. The by-product occurred after the double addition in which 
the lactone ring was opened while amide and primary alcohol functional groups 
formed. Also, Fossey’s group reported the second addition of primary amine only 
occurred after 1,4-conjugate addition completely. Therefore, only one equivalent 
primary amine was added into each reaction to avoid a second addition to form 
undesired product.  Nevertheless, even reaction use excess amounts of secondary 
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Methyl N-propyl 78 
2 7b 
 
Methyl Isopropyl 32 
 
N-Methylpropylamine and N-Isopropylmethylamine, two acyclic aliphatic secondary 
amines, are structural isomers which have the same chemical formula (C4H11N). The 
difference between these two amines is that N-Isopropylmethylamine has a methyl 
group attached to the secondary carbon and this attached group gives it a side chain 
which is slightly bulky. When compared to each other, both compounds may found 
different medical properties of the pair of isomers. They were reacted with tulipane to 
undergo the addition reaction to afford target product 7a and 7b. Additionally, the 
yields between them were so different that 7a is twice as high as 7b. To explain the 
difference, one possible reason is that structural isomers process different chemical 
reactivity such as the effect of steric hindrance of the bulky side chain of N-
Isopropylmethylamine. 
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Four cyclic aliphatic amines, namely Pyrrolidine, Piperidine, Morpholine and 1-
Methylpiperazine, were synthesised with 6 to obtain target 8 (a-d) by general method 
A. As compound 8a has a five-membered ring and 8b has a six-membered ring. 
Comparing both products to make a better understanding of the biological activity of 
ring size is one goal of this project. 
Target 8c and 8d also contain a six-membered ring, but 8c adds an oxygen atom into 
the six-membered ring and a nitrogen atom was replaced by a carbon while attached 
an N-methyl group to form 8d. Therefore, we can see the different chemical 
properties and biological activity between the conditions; namely that the six-
membered ring structure contains a heteroatom and does not have a heteroatom. In 
addition, only compound 8d has a relatively lower yield (61%) compared with other 
three cyclic amine derivatives (the yields were in the range 81-91%). 
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Methyl Methyl 70 
2 9b 
 












Isopropyl Isopropyl  
5 9e 
 
Benzyl Benzyl  
In this symmetrical secondary aliphatic amine series (Table 7), only two target 
compounds (9a and 9b) were successfully synthesised using the general method 
(Method A). The yield of dimethyl tulipane derivative 9a is twice than 9b. With 9b 
increasing the chain length in the propyl group, different chain length of the alkyl 
moiety of 9a and 9b may also affect their biological activity. 
However, for compound 9c, no product was observed after 24 hours by TLC-scanning. 
Hence, a suitable base (2 equivalents potassium carbonate) was added into the 
reaction to deprotonates amines and makes it more nucleophilic; this process also 
makes the whole reaction faster and more effective. After 12 hours, the TLC plate 
showed a new spot and reaction mixture was purified by column chromatography on 
silica with a dichloromethane and methanol eluent system. The proton NMR spectrum 
was quite complex and did not exactly match what we expected which products 
observed turned out to be disappointing. One possible reason is that the expected 
product might have been decomposed during the process of column chromatography. 
For target 9d and 9e, a similar situation occurred as the amines both contain the bulky 
side chain. This seems a possible reason to understand why the reactions were not 
complete after a longer period (more than 30 hours) by TLC-scanning. Both reaction 
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mixtures were purified by column chromatography on silica with a dichloromethane 
and methanol solvent system. However, no expected product was present in either 
1
H 
NMR spectrums respectively. Both reactions have been repeated under the same 
previous conditions to exam if any better results can be obtained. However, both 
repeated reactions failed again as a result of disordered 
1
H NMR spectrums obtained. 
The possible reasons for the failure of these reactions are the general space issues in 
chemical reactivity. In other words, if the nitrogen in amines has large substituents 
attached, it may hinder the ability to generate a new C-N bond. Also the steric effects 
of bulky substituents of amines may destabilise the compound and hence lead to the 
unstable and rapid decomposition of two targets 9d and 9e. 













1 10a L-Alanine 
 
Methyl 33 
2 10b Glycine 
 
Hydrogen 25 
3 10c L-Valine 
 
Isopropyl 20 
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4 10d L-Phenylalanine 
 
Benzyl 13 
Compound 10a, 10b, 10c and 10d have used the amino acid as the starting 
material(SM). A carboxylic functional group of the synthesised compounds might 
play an important role of in vivo testing. For example, the amino acid reacts with 
another amino group to generate peptide chains. Also the different R group of amino 
acids, such as hydrogen, methyl, isopropyl and benzyl side chain, can give a better 
understanding of whether the effects contained a smaller or larger size substituent in 
organic chemistry and biochemistry. 
However, further purification of those compounds became difficult due to greater 
water solubility. A new method (Method B) was developed in which one equivalent 
amino acid and excess tulipane were used in reaction. Product formation was judged 
by TLC and reaction mixture reduced to dryness in vacuo. The residue was washed 
with ethanol three times to afford a colourless crystalline solid.  
Compound 10a and 10b have been successfully synthesised by implementing the new 
reaction procedure. The purity of both compounds is assessed by mass spectrometry, 
NMR (proton and carbon nuclear magnet resonance spectrometry) and IR. Compound 
10c also used the new method to synthesise with 10a and 10b. The crude product of 
10d was washed by using numerous common organic solvents that are supplied in the 
lab to obtain pure product. However the results of the proton NMR were similar to the 
crude product, as the 
1
H NMR spectrum still showed few impurity peaks. Carbon C-
18 column on CombiFlash Chromatography System was used to purify this crude 
product later (water and acetonitrile mixture as solvent system), but 10d cannot show 
a better purity. Even so, the compound 10c proves successful synthesised by Proton 
NMR, Carbon NMR, IR and mass spectrometry. This situation is not ideal but 10d 
can still be used initially to detect whether it has anti-cancer activity or not. 
Compound 10c was successfully synthesised by this new method and judged by 
Proton NMR, Carbon NMR, IR and mass spectrometry. However, purification of this 
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compound is also difficult. The product showed very low solubility in most common 
solvents and was only soluble in water. So, compound 10c cannot be purified by 
normal column chromatography. Even after being purified later by using a 
recrystallization method, the product purity was still not improved. Then, attempts 
using C-18 Column for further purification yielded a clear separation that was 
achieved by using water and acetonitrile mixture solvent systems. 
Therefore, the reaction yields of amino acid derivatives were in a lower range of 13–
33%. The yield of 10c and 10d especially have been reduced during the difficult 
purification process. 




















Hydrogen Benzyl 85 
 
Two thiols, 2-mercaptoethanol and benzylmercapton, were reacted with tulipane 
undergoing the Michael addition reaction to afford target product 11a and 11b 
respectively. Compound 11b is a sulphur derivative of 6b in which a nitrogen atom 
was replaced by a sulphur atom. Thiol is an organosulfur compound that contains an 
SH functional group; it is the same as amine which is also a common ‘soft’ 
nucleophile. As the β carbon of α,β-unsaturated lactone is soft electrophile, both soft 
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nucleophile and electrophile are favoured to react with each other, and to and form a 
new C-S bond undergoes 1,4-conjugate reaction. Thiol groups play a crucially 
important role in biochemistry study, the compounds have worked through the 
conjugate addition reaction with intercellular thiol groups. As mentioned before, 
compared with amine derivatives, it is more difficult for the thiol derivatives to 
undergo an irreversible Michael addition reaction in vitro, during which the 
intercellular thiol groups cannot degenerate this thiol derivative to form free α,β-
unsaturated lactone very easily. Therefore, compound 11a and 11b can be used as an 
indicator, an inactive compound, to judge the biological activity of other tulipane 
derivatives in in vitro studies. 
Compound 11a and 11b showed no product formation after 24 hours by TLC. One 
possible reason is that the thiol group shows a relatively lower nucleophilicity 
compared to amine. Therefore, a suitable base, triethylamine (TEA), was added into 
the reaction to increase the nucleophile of thiol group. After further 12 hours, two 
targets were obtained by TLC-scanning and isolated using the general experimental 
procedure (Method A). The purity of both compounds was assessed by mass 
spectrometry, NMR and IR. Because the additional base was used, both compounds 
11a and 11b obtained a relatively high yield (78% and 85% respectively).  















Hydrogen N-2-hydroxyethyl 71 
2 12b 
 
Methyl N-2-hydroxyethyl 91 
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Ethyl N-2-hydroxyethyl 61 
4 12d 
 
Hydrogen N-2-methoxyethyl 82 
5 12e 
 
Methyl N-2-methoxyethyl 48 
 
Two secondary aliphatic amines derivatives (7a and 7b) have been discussed in Table 
5 (entry 1 and 2). Compared with 7a and 12b, the relationship between both targets is 
that the propyl chain of 7a has been converted to an ethanol to form 12b. Compound 
12a and 12c, also contained an alcohol functional group, have the same R
2 
substitute 
N-2-methoxyethyl side chain compared with 12b. Compare the three amino alcohol 
derivatives, 12a, 12b and 12c, the only difference is that the compounds contain 
different alkyl moiety which increased the chain length of R
1
. Therefore, to compare 
the structure-activity relationship and water solubility of the compound including OH 
group or not are one of the goals of this experiment. The reaction yield of 12a and 12c 
were in the range 61–71%. Target 12b obtained the highest yield (91%) in Table 10. 
Also, the purity of those compounds was assessed by mass spectrometry, proton NMR, 
carbon NMR and IR. 
In this project, two amino ether tulipane derivatives (12d and 12e) have also been 
synthesized by the general experiment method (Table 10, entry 4 and 5). The 
difference between compound 12a and 12d is that an N-methyl group has replaced the 
hydrogen to attach the oxygen atom and converted to an ether functional group as 
same as target 12b and 12e. Therefore, comparing those targets which contain an 
alcohol or ether functional group to find out which one has obtained the higher 
aqueous solubility or better biological activity is another goal to achieve in this 
project. 
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NB: Compound 13c is a major by-product of compound 13a when use acyl chloride as SM, and this 
issue will be discussed in chapter 2.4 
Compound 12a and 12d, as secondary amine analogues, are available to undergo a 
further reaction. Therefore, two amide tulipane derivatives (13a and 13b) have been 
synthesised in Table 11, which is judged by mass spectrometry, proton NMR, carbon 
NMR and IR. Derivative 13a and 13b have undergone a two-step reaction. The first 
step has been used the general method (Method A) to synthesise the secondary amino-
tulipane derivatives (12a and 12d respectively). Later, the amide derivatives were 
formed by an alkylation reaction (Scheme 7). The reaction yield of amide tulipane 
derivatives 13a and 13b were in the range of 48–51%. A possible benefit is that the 
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enzymes which live in the biological system may slowly decompose the amide and 
allow the compound to stay in inactive state longer. Therefore, derivatives could be 
breaking down to free α,β-unsaturated lactone slowly while losing biological activity 
by being substituted by biological nucleophiles quickly before the target was found. 
In addition， derivative 13c (entry 3) is a major by-product of compound 13a. This 
issue will be discussed in chapter 2.4. 
 
2.4 By-Product Study 
As mentioned above, the secondary amine derivative undergoes a
 
second modification 
to produce a novel amide derivative. Firstly, an excess amount of acetyl chloride was 
reacted with compound 12a (secondary amine derivative) in which a by-product was 
obtained (Route A).  
 
Scheme 6: Compound 13a was synthesised by using two different starting materials. Conditions: A) Excess Acetyl 
Chloride; B) 1 equiv Acetyl Chloride; C) Excess (1.2 equiv) Acetic anhydride; D) 1 equiv Ethanolamine 
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One possible reason the by-product is generated is due to the nitrogen atom having a 
more reactive lone pair than oxygen (nitrogen being less electronegative than oxygen), 
which makes it more nucleophilic to attack the carbonyl in aryl chloride. However, 
excess of acetyl chloride will push the reaction forward, because it is reacting with the 
amino group to form an amide and then also reacting with alcohols to form esters 
(Route A). Therefore, if only one equivalent of acetyl chloride is used in the reaction, 
the desired product can be isolated preferentially. In fact, one equivalent of acetyl 
chloride was used and both the desired and undesired products have been obtained in 
parallel. The most likely reason is that acetyl chlorides reacts with the amino group 
and alcohol to form amide and ester respectively and both reactions occurred at a 
similar rate. (Route B). 
 
Figure 16: Proton NMRs of compound 13a and 13c. 
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Scheme 7: Mechanism for formation of the compounds 13a and 13c 
Amide and ester function group of the by-product were identified (13c) via Infrared, 
Proton and Carbon NMR spectroscopy. IR (Infrared) shows three C=O groups 
stretches in the range of 1770-1640 cm
-1
 (amide, ester and lactone function group).
1
H 
NMR showed two singlets between 2 to 2.2 ppm whose peaks belong to each of the 
two methyl groups of compound 13c. Also, 
13
C NMR showed 11 peaks with 11 
different carbon environments which two methyl groups at 21.7 and 21.0 ppm 
respectively. All information above has suggested a by-product synthesised during the 
Route A and Route B (see Scheme 6 and Scheme 7). Therefore, acetic anhydride was 
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used to replace the acetyl chloride to react with tulipane derivative (12a) and this 
reaction forms the desired product after 24 hours (Route C). 
 
2.5 Synthesis of Diastereoisomers 
Both amino acid derivatives 10a and 10c constitute a pair of diastereoisomers 
respectively. The amino acid as a starting material has contributed to a stereogenic 
centre while another stereogenic centre was generated undergoing the Michael 
addition reaction. In general, the chemical environments of pair of diastereoisomers 
are different, which has been shown in the different symmetry. Therefore, the 
diastereotopic protons, such as proton in N-methyl group of 10a and N-isopropyl 
group of 10c, can have different chemical shifts and coupling constants. Hence, 
proton NMR spectroscopy can be used to differentiate the pair of diastereoisomers 
and determine the diastereomeric ratio. 




Amino acid used Syn(1) Anti(2) 
10a L-Alanine 
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2.5.1 L-Valine Derivatives (10c-1 and 10c-2) 
By analysing the structure of L-Valine derivatives, the proton in isopropyl group 
coupled with diastereotopic proton next to it give two doublets in the spectrum. 
According to the 
1
H NMR spectrum of the material isolated from the reaction, the pair 
of doublet peaks can be easily identified and it was found out the CH groups shift 
from 3.35 ppm to 3.55 ppm. When analysing the coupling tree of CH groups there is a 
coupling constant of 4 Hz (Jb) within the doublet and also the two doublets are 
separated in 0.2 ppm. 
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Figure 17: Proton NMR of compound 10c-1 and 10c-2 and coupling constants between the alpha proton and a 
proton of isopropyl group next it 
Figure 17 shows diastereoisomers represented by the doublet peaks. Now it can be 
understood more easily about which peaks respond to each doublet. The ratio of pair 
of diastereoisomers is determined by calculating the integration of each doublet peak. 
Therefore, crude analysis of the diastereomeric ratio of two diastereoisomers 10c-1 
and 10c-2 with 
1
H NMR was estimated around 37:63 or 63:37. 
 
2.5.2 L-Alanine Derivatives (10a-1 and10a-2) 
For proton NMR spectrum of the material isolated from the L-Alanine reaction, we 
have defined a ratio of pair of diastereoisomers by analysing the coupling between the 
N-methyl group and the alpha proton next to it. 
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Figure 18: 1H NMR of compound 10c-1 and10c-2 and coupling constants between two methyl and beta protons 
The alpha hydrogen shows two quartets at 3.6 ppm and these two quartets are 
overlapping each other. However, both quartets can be easily recognised with a 
coupling constant of 9.6 Hz (JB). Therefore, the peaks of each quartet were identified 
and the integrating of each quartet peak has obtained the diastereomeric ratio of two 
diastereoisomers around 50:50. 
 
2.6 Parthenolide Modification 
For clinical drug studies discussed above, there is a major issue that PTL has very 
poor water solubility. In the past few years, a series of PTL analogues have been 
synthesised by Michael addition reaction which had higher water-solubility than PTL 
(Scheme 4). One advantage of this type of reaction is that only a single desired 
product is formed and the stereospecificity of the Michael addition reaction is 
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established. The reason is that the intermediate enolate of the conjugate addition from 
the endo face undergoes a 1,3-diaxial interaction of hydrogen on carbon 6, axial 
hydrogen on carbon 8 and two hydrogen on carbon 13.  
The rationale of PTL derivatives is same as tulipane derivatives in which tulipane 
have successfully passed the preliminary chemical reactivity test (as discussed in 
chapter 2.3). It has proven that tulipane complies with the PTL theory. 
The eighteen PTL derivatives, 14a-h and 15a-j, that have been successful synthesised 
and the reaction yield of each derivative can be found in Table 14; almost all the 
derivatives were synthesised using the general experimental method as outlined above 
(Scheme 4). Only the amino acid derivatives were synthesised using a developed 
procedure in which methanol and water mixture were used as solvents and an 
appropriate base (potassium carbonate) added in the reaction. PTL was reacted with 
1.2 equivalent different types of amines and amino acids, further with the purification 
of the reaction mixture by column chromatography (silica, ethyl acetate and hexane as 
the solvent system). The purity of PTL derivatives was assessed by mass spectrometry, 
proton NMR, carbon NMR and IR. In addition, all aminoparthenolide derivatives 
prove that only R configuration was displayed at carbon 11 during the Michael 
addition reaction as judged by Specific rotation (this can be found in the experimental 
section). Only one PTL derivative (14h) has the S configuration at carbon 11; the thiol 
group undergoes the Michael addition on the enone olefin of PTL and obtained the (S) 
stereocentre in which the specific optical rotation of this compound was shown a 
positive value. A final compound library of tulipane and PTL derivatives can be seen 
in Table 13 and Table 14. 
 
 
Figure 19: Amino derivative and Thiol derivative have different stereocentres at C-11 
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 0.500 0.480 0.009 0.28 
2 6a 
 
60 -0.610 -0.040 -0.006 0.34 
3 6b 
 
61 0.860 1.480 1.448 0.35 
4 7a 
 
78 0.610 0.950 0.758 0.17 
5 7b 
 
32 0.550 0.780 0.860 0.16 
6 8a 
 
86 0.520 0.440 0.483 0.04 
7 8b 
 
91 0.84 0.86 0.841 0.01 
8 8c 
 
81 -0.370 -0.280 -0.423 0.07 
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61 -0.250 -0.120 -0.380 0.13 
10 9a 
 
70 -0.290 0.120 -0.023 0.21 
11 9b 
 
35 1.510 1.770 1.539 0.14 
12 10a 
 
33 -1.020 -0.500 -0.319 0.36 
13 10b 
 
25 -1.420 -0.990 -0.845 0.30 
14 10c 
 
20 -0.220 0.390 0.336 0.34 
15 10d 
 
13 0.250 1.180 1.126 0.52 
16 11a 
 
78 0.190 0.170 -0.604 0.45 
17 11b 
 
85 2.140 2.420 1.815 0.30 
18 12a 
 
71 -1.020 -0.770 -0.971 0.13 
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91 -0.390 -0.732 -0.800 0.22 
20 12c 
 
61 -0.370 -0.060 -0.309 0.16 
21 12d 
 
82 -0.570 -0.410 -0.452 0.08 
22 12e 
 
48 -0.350 -0.030 -0.213 0.16 
23 13a 
 
51 -0.770 -1.120 -0.908 0.18 
24 13b 
 
48 -0.570 -0.410 -0.452 0.08 
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 2.770 2.070 1.280 0.75 
2 14a 
 
79 2.890 2.540 2.033 0.43 
3 14b 
 
36 2.820 2.370 2.135 0.35 
4 14c 
 
83 2.800 2.030 1.758 0.54 
5 14d 
 
92 3.110 2.450 2.116 0.51 
6 14e 
 
84 1.910 1.320 0.852 0.53 
7 14f 
 
43 3.790 3.360 2.814 0.49 
8 14g 
 












2.030 1.470 0.895 
 
0.58 
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36 1.660 1.550 1.281 0.19 
12 15c 
 
28 0.850 0.600 0.430 0.21 
13 15d 
 
36 1.250 1.100 0.956 0.14 
14 15e 
 
34 2.530 2.770 2.401 0.19 
15 15f 
 
26 2.060 1.980 1.611 0.24 
16 15g 
 
21 1.250 0.820 0.304 0.47 
17 15h 
 
77 1.910 1.540 0.966 0.48 
18 15i 
 
57 1.920 1.560 1.062 0.43 
19 15j 
 
23 1.700 1.180 0.823 0.44 
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2.7 Application of Lipinski's rule to derivatives 
Christopher A. Lipinski, a senior medicinal chemist, proposed five basic rules 
(Lipinski rules) to quickly screen potential prodrugs in 1997. If a compound complies 
with all the requirements of Lipinski rules, it will usually appear to have better 
pharmacokinetic properties, higher bioavailability in vivo and thus be more likely to 
become a suitable oral medication. Therefore, Lipinski rules have been used to 
primarily screen all derivatives to examine compounds that are suitable for further 
biological studies. The main Lipinski rules are: 
1. No more than 5 hydrogen bond donors  
2. No more than 10 hydrogen bond acceptors  
3. A molecular mass less than 500 daltons (g/mol) 
4. A value of log P no greater than 5 
 
Using these conditions to analyse tulipane derivatives and PTL derivative, the results 
show that none of them have contained either more than 5 hydrogen bond donors or 
10 hydrogen bond acceptors. Molecular weight of each compound was less than 500 
g/mol and as presented in Table 13 and Table 14, the value of logP of each 
compound is not greater than 5. Therefore, all compounds comply with the 
requirements of the primary drug testing. The result suggested that the derivatives are 
suitable for evaluating their anti-cancer activities using three different types of 
chronic lymphocytic leukaemia (CLL) cell lines in vitro. 
 
2.8 Predicting logP of derivatives using different software 
Water solubility is a common issue in drug studies because it affects the biological 
activity as well as toxicity. To better understand the water solubility of tulipane 
derivatives and PTL derivatives, the octanol-water partition coefficient (logP) of each 
compound was calculated and a rational level of molecular hydrophobicity was 
measured. As logP presents the effects on biological activity when increasing water 
solubility; thus logP can be used to identify whether the drug effectiveness of PTL is 
limited by water solubility or not. The simple and reliable experimental method of log 
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P measurement is the shake-flask technique. However, the measurement of log P 
using shake-flask technique is a time-consuming and material-consuming method. 
Therefore, in this project, a faster and easier theoretical calculation method was used 
to predict logP values that quickly screen compound as to whether they comply with 
the requirement of Lipinski rules or not. Each compound were calculated with 
ChemBioDraw software and two molecular property website (Table 13 and Table 14) 
and all software were predicting log P value by chemical structure of each compound . 
There were two different calculation methods used: atomic-based prediction and 
fragment-based prediction. 
In summary, the structure solubility data of tulipane and PTL derivatives are shown in 
Table 13 and Table 14. The derivatives which contained aromatic groups exhibit 
significantly less aqueous solubility compared to those derivatives from aliphatic 
amines. Comparing the cyclic aliphatic derivatives, such as 8a to 8b and 14c to 14d, 
ring size played an important role in water solubility, where an increase in the ring 
size reduced the solubility. However, if the six-membered rings contained a 
heteroatom the solubility was significant increased such as in 8b-8d and14d-14e. 
Amino acid derivatives exhibit distinct water solubility. Due to the variable R groups 
found in amino acids, such as hydrogen, methyl, isopropyl and benzyl, the bigger the 
side chain, the greater the reduction in solubility (10a-d and 15c-f). 
Almost all tulipane and PTL derivatives had increased aqueous solubility compared 
with both parent compounds (1 and 5), especially those derivatives containing alcohol, 
ether and amide functional groups. The solubility of those compounds was much 
better in water than tulipane or PTL. 
The standard deviation (SD) of predicted log P data for derivatives was shown in 
Table 13 and Table 14.  The general SD value of derivative was quite high, which 
was not only caused by software using different computation mode, atomic-based 
prediction or fragment-based prediction calculation method; also, based on the same 
fragment-based prediction calculation method, the molecular structure could be 
broken down in various ways and the contribution of different fragments will produce 
various values of log P. Moreover, the reliability of calculated log P values are still 
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limited. Even the aim of this theoretical calculation study was not to work out the 
exact log P value for each compound, but to highlight the reliability of pesticide log P 
values in a series of experimental measurements is indispensable work in future. 
Furthermore, the experiment data should be compared with the calculated Log P 
values, to find which calculation method is closer to reality. 
 
2.9 Biological Activity Studies 
Three chronic lymphocytic leukaemia (CLL) cell lines (MEC1, CII and PGA) were 
obtained from the American Type Culture Collection (ATCC). This is the first study 
of anti-cancer activity of PTL and tulipane using PGA and Mec1 cell line. All cell 
lines were previously established from peripheral blood; refer to Table 15.  
Table 15: Details of PGA, CII and MEC1 cell lines.46,47 
Cell 
line 
From Established Information 
PGA man From 
peripheral 
blood 
Epstein-Barr Virus (EBV)-immortalized 







Cell line includes a type-A glucose-6-
phosphate dehydrogenase (G6PD) pattern 












Shows the IGHV4-59 rearrangement with 
patient peripheral leukemic clone. 
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2.9.1 Parthenolide and Derivatives 
2.9.1.1 Determining the effective concentration range and treatment time for PTL. 
Parthenolide and eight PTL derivatives (14a-h) were tested for their cytotoxic activity 
on CLL cell lines. First of all, PTL was tested on the CLL cell lines CII and PGA.  
Propidium iodide (PI) was used for the measurement of cytotoxic activity. PI is 
excluded from a viable cell by the intact plasma membrane. In a dead cell, however, 
the plasma membrane is compromised thus allowing PI to enter and intercalate with 
nucleic acids enabling the detection and quantification of dead cells by flow 
cytometry. There are two factors to examine in the first biological experiment: 
1. Effect of concentration range of PTL against PGA and CII cell lines. 
2. Effect of time. 
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Figure 20: Dose response curve showing effect of increasing concentrations of parthenolide on CLL cell lines CII 
and PGA after 24hours. Student’s test was used to compare treated cells with untreated cells. 
 
Figure 21: Dose response curve showing effect of increasing concentrations of parthenolide on CLL cell lines CII 
and PGA after 48hours. Student’s Ttest was used to compare treated cells with untreated cells. 
 
Treatment of PGA and CII cells with increasing dose of PTL for 24 hours resulted in 
an significant increase in cell death at 5 and 10 µM PTL; see Figure 20. This effect 
was enhanced with increased treatment time; see Figure 21. 
For the concentration ranging from 0 to 10 µM, Figure 20 and Figure 21 have 
showed the PGA cell line was more sensitive than CII cell line. The amount of cell 
death of both cell lines was increasing by about 10% with longer incubation. However, 
with both time points the PGA cell line was more sensitive than CII. Therefore, PTL 
was effective over the concentration range of 0-10 µM following 24 hours’ treatment. 
These concentrations were used in subsequent experiments. 
2.9.1.2. Comparison of PTL and PTL derivatives at 10 µM. 
The next step of this study was to compare the effectiveness of PTL and PTL 
derivatives in CII, PGA and MEC1 cells.  
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Figure 22: PTL and 14a-h against three CLL cell lines at the same time. Student’s test was used to compare 
treated cells with untreated cells 
In initial experiments, PTL and the corresponding derivatives 14a-h were tested on 
PGA, CII and MEC1 cell lines using a single concentration of 10 µM. The data shown 
is the mean of three independent assays set up in triplicate, Figure 22. Compared to 
control cells, five of eight compounds showed significant levels of killing in all cell 
lines, Figure 22. The anti-cancer activity of all derivatives was generally reduced 
compared with PTL. When compared to PTL, compounds 14a, 14b, 14c, 14d and 14f 
did not show significant reduction in killing activity. Compound 14e and 14g did not 
show any killing activity, indicating that amino modification blocks the anti-
leukaemic activity of PTL as well as the benzylmercapton adduct (14h). 
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2.9.1.3. Determination of LD50 of biologically active PTL derivatives. 
 
Figure 23: Dose response curve showing effect of increasing concentrations of PTL and derivatives on PGA cell 




Figure 24: Dose response curve showing effect of increasing concentrations of PTL and derivatives on CII cell 
line after 24 hours 
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Figure 25: Dose response curve showing effect of increasing concentrations of PTL and derivatives on MEC1 cell 
line after 24 hours 
A series of dose response assays were used to determine the LD50 of each of the 
biologically active PTL derivatives in CII, PGA and MEC1 cells. The LD50 were 
calculated using the dose response curves shown in Figure 23, Figure 24 and Figure 
25. PTL anti-leukaemic activity has been shown to be dependent in the α-methylene-
γ-butyrolactone, as shown in Table 16. A possible reason for LD50 of all derivatives 
being higher than PTL is due to the hampered nucleophilicity when amine was added 
to the Michael accepter, α-methylene-γ-butyrolactone moiety. All compounds were 
shown to have an LD50 in the low µM range in all CLL cell lines tested. 
Table 16: The LD50 values of PTL and five derivatives which against three CLL cell lines 
Entry Target No. Structure  LD50  (µM) 
(PGA) (CII) (MEC1) 
1 1 
 
5.4 5.6 6.8 
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8.7 8.2 8.8 
3 14b 
 
7.5 7.6 7.9 
4 14c 
 
9 9.8 9.2 
5 14d 
 
6.7 6.6 7.4 
6 14f 
 
7.4 8.5 8.1 
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2.9.2 Tulipane and Derivatives 
2.9.2.1. Determining effective concentration range for tulipane 
 
Figure 26: Dose response curve showing effect of increasing concentrations of tulipane on PGA cell lines after 24 
hours. Student’s test was used to compare treated cells with untreated cells 
Compared to PTL, the structurally similar molecule, tulipane, was used to optimise 
the derivatisation of PTL. This resulted in the generation of a panel of tulipane 
derivatives with the same additional groups as in the PTL panel. Therefore, we have 
investigated the effect of these modifications on the biological activity of tulipane. 
The effective concentration range of tulipane was determined in Figure 26. Tulipane 
induced significant levels of cell deaths at 5 µM and above. 
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2.9.2.2. Comparison of tulipane and tulipane derivatives at 20 µM 
Figure 27: Tulipane and derivatives were tested on CLL cell lines after 24 hours. Student’s test was used to 
compare treated cells with untreated cells 
As an initial screen for tulipane derivatives with biological activity, CLL cell lines 
PGA, CII and MEC1 were treated with 20 µM of each derivative for 24 hours. In this 
assay, tulipane consistently demonstrated significant killing of all three cell lines. 
However, all killing activity was lost upon derivatisation in all cases. 
In this series of experiments, the anti-leukaemic activity of PTL derivatives and the 
analog tulipane derivatives were determined in CLL cell lines. Five of eight 
derivatives, 14a, 14b, 14c, 14d and 14f, showed a similar anti-leukaemic activity to 
parent compound. The LD50 value of PTL and five active derivatives was identified in 
the range of 6µM to 10 µM in PGA, CII and MEC1 cell lines. The PGA cell line 
showed response to these five derivatives and the obtained LD50 was lower than the 
others, whereas any modification of tulipane resulted in loss of activity. The five 
active PTL derivatives 14a, 14b, 14c, 14d and 14f will be used for further 
experiments in vivo. Therefore, the calculated logP should be compared with 
biological activity of derivatives and PTL; it will either be able to support or deny the 
hypothesis that the low water solubility of PTL is the reason it does not function well 
as a drug in whole organisms.  
Comparing PTL and tulipane, both compounds have shown significant levels of 
killing activity on CLL cell lines. Furthermore, tulipane induced a lower level of cell 
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death than PTL at the same concentration, suggesting that the specific cyclic ten-
membered ring skeleton jointing with α-methylene-γ-butyrolactone moiety enhances 
the anti-leukaemic activity.  
Comparing the difference between PTL derivative and tulipane analog, tulipane 
derivatives had relatively better structural stability than PTL derivatives. Therefore, it 
was more difficult for the tulipane derivatives to carry out the retro Michael addition 
reaction and release the free exocyclic double bond on the α,β-unsaturated lactone. On 
the other hand, the specific skeleton of PTL indicated that it may destabilise the 
lactone moiety of derivative and regenerate free PTL more easily.  
Unlike amino PTL derivatives, thiol PTL derivative had not displayed any anti-
leukaemic activity in the experiment. This may due to the chemical properties of the 
thiol group, which is a weaker electrophilic-leaving group compared to the amino 
group. Therefore, thiol derivative was more difficult to convert into free PTL 
undergoing the retro Michael addition reaction in vitro.  
Combining the experimental data with literatures, PTL had obtained a significant 
level of killing against both AML and CLL cells, but the literature LD50 value of PTL 
against AML cell was only 1.7 µM and the LD50 value of PTL against CLL in this 
series experiment was around 6 µM. Moreover, the LD50 value of active 
aminoparthenolide analog was also identified in a relatively low concentration range 
against AML compared to CLL cells. 
There is often a difference between the results of in vitro and in vivo studies. Because 
in in vivo studies, compounds are tested in living organisms and undergone an 
uncontrolled environment comparing to the conditions in vitro study. Without the 
issue of water solubility of PTL, there was still another important condition, the non-
selective reactivity of PTL, which hampered its clinical translation in vivo. Many 
different thiol groups exist in living cells and result in PTL being rapidly trapped by a 
Michael addition of the undesired targets. This might cause low anti-cancer activity 
and side effects in real applications. Therefore, this modification of PTL might be 
able to overcome this non-selective problem of PTL. Derivatives may show better 
effect compared to the parent compound during in vivo tests.  
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Chapter 3: Conclusion and Future Work 
In summary, the major objectives of this study have been achieved. First of all, a 
recombining extraction and purification procedure has been used for the isolation of 
PTL from feverfew. Secondly, we found that the maximum amount of PTL can be 
extracted from golden feverfew in the post-flowering period. For different types of 
feverfew, plant matter containing seeds, post-flowering season, was much richer in 
PTL than in pre-flowering season. In addition, the colourless crystalline solid of PTL 
was fully characterised by melting point, mass spectrometry, proton NMR, carbon 
NMR and IR and the structure has also been confirmed by single crystal X-ray 
analysis. 
Thirdly, twenty-three tulipane derivatives have been successful synthesised. All 
compounds have screened and passed the preliminary test according to Lipinski rule. 
Most of tulipane derivatives have been tested on a CLL cell line. However, the results 
have shown those compounds have significantly lost the anti-cancer activity 
compared with the parent compound. In contrast, tulipane has successfully passed the 
preliminary chemical reactivity test. It has proven that tulipane complies with the PTL 
theory. 
Eighteen PTL derivatives, after modification by the same functional group as tulipane 
derivatives, were synthesised successfully at the same time. Compounds were also 
passed the preliminary test by Lipinski rules. Eight of the PTL derivatives appeared to 
be effective against CLL cell line; and the preliminary biological results showed five 
of them to be active compounds (14a, 14b, 14c, 14d and 14f) which showed similar 
anti-cancer activity compared with parent. Those potential compounds will be tested 
in the next stage of biological studies in vivo. 
Finally, the water solubility of those derivatives was evaluated and results showed 
that derivatives contained an aromatic group exhibiting relatively less aqueous 
solubility. The larger ring size of cyclic aliphatic derivatives has shown less water 
solubility. If a heteroatom is included in the ring structure, then the solubility was 
significantly increased. Amino acid derivatives exhibit distinct water solubility due to 
the different R group of amino acids. Finally, compounds that showed greater water 
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solubility than tulipane and PTL contained an alcohol, ether or amide functional 
group. 
The researcher’s aim of future work of organic chemistry will be focusing on High 
Performance Liquid Chromatography (HPLC) works. The two diastereomers of 
amino acid tulipane derivatives, which could separate via HPLC, are very crucial; and 
HPLC is an advanced purification method to improve the purity of compound. Lastly, 
the water-solubility of few compounds should be tested and the experiment data 
should be compared with the calculated Log P values to find which theoretical 
calculation method is closer to reality. 
It is difficult to understand the structural-activity relationship of derivatives before all 
derivatives have been tested and all biological experiments have been finished. 
Therefore, in future biological work, unexamined remaining PTL derivatives (15a-g) 
should also be tested against CLL cell lines. By doing so, researchers will be able to 
expand and understand the anti-cancer activity relationship between the different 
structure functionality of compounds.  
Moreover, a series of possible experiments aiming to look at the effect of those novel 
compounds on redox homeostasis and NF-kB signalling to identify mechanism of 
action should also be established. 
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Chapter 4: Experimental 
4.1 General 
All commercially available solvents and reagents were used without further 
purification.  Proton NMR spectra were recorded at 300 MHz on a Bruker AVIII300 
NMR spectrometer and at 400 MHz on a Bruker AVIII400 NMR spectrometer. 
Carbon NMR spectra were recorded at 100 MHz on a Bruker AVIII400 NMR 
spectrometer at room temperature and are proton decoupled. Data was processed with 
Mestrec version 5.2.5-4731 and Topspin 2.0 (Version of: Nov 9th 2006). Chemical 
shifts (δ) are reported in ppm relative to TMS (δ 0.00) for the 
1
H NMR and to 
chloroform (δ 77.0) for the 
13
C NMR measurements, coupling constant J are 
expressed in Hertz. Mass spectra were recorded with electrospray MS Waters LCT 
Time of Flight Mass Spectrometer and with EI (GC/MS) Waters GCT Premier Time 
of Flight Mass Spectrometer. Infrared Spectra were recorded on a PerkinElmer 
100FT-IR spectrometer at room temperature. Melting points were measured using a 
SMP10 melting point apparatus. Specific rotations were recorded on an Optical 
PolAAr 2001 automatic polarimeter at room temperature. X-ray crystal structure was 
recorded on an Agilent SuperNova X-ray diffractometer with an Atlas detector using 
an X-ray source with wavelength 1.5418 Angstroms. 
 
4.2 Novel Extraction  
Plant matter was added into water (10 g per 100 ml) and the solution was stirred at 
80 °C for 10 minutes. The filtrate was allowed to cool at the room temperature. Then 
use chloroform to wash it 3 times (3 ×500 ml), the chloroform portions were 
combined and reduced to dryness under reduced pressure to afford a dark green 
residue. The purification of the residue was done by column chromatography (EtOAc 
with Hexane) and then recrystallized using the same solvent system EtOAc / Hexane 
to afford parthenolide. 
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4.3 Experimental Procedures 
Method A: The amine (Excess) and α,β-unsaturated lactone were stirred in methanol 
at room temperature for 24 hours. Reaction progress was monitored by Thin-layer 
chromatography. The solvent was removed under reduced pressure and product was 
isolated by column chromatography over silica gel. 
Method B: The amino acid and α,β-unsaturated lactone (Excess) were stirred in 
methanol and water mixture at room temperature for 24 hours. An appropriate amount 
of TEA (or K2CO3) has been used in this method. Reaction progress was monitored 
by Thin-layer chromatography. Then the target compound was reduced to dryness in 
vacuum and future washed the compound with Ethanol three times to afford a 
colourless crystalline solid. 
Method C: The Acetic anhydride and tulipane derivative 12a or 12d were stirred in 
DCM at room temperature for 24 hours. Reaction progress was monitored by Thin-
layer chromatography. The solvent was removed under reduced pressure and product 
was isolated by column chromatography over silica gel. 
All compounds were fully characterised by melting point (solid), specific rotation 
(PTL derivatives only) mass spectrometry, proton NMR, carbon NMR and IR. 
 
4.4 Biological Work  
4.4.1 Cell lines and cell culture 
Three Chronic Lymphocytic leukaemia (CLL) cell lines (MEC1, CII and PGA) were 
obtained from the American Type Culture Collection (ATCC). Also PGA and Mec1 
cell lines have never been used before to test the anti-cancer activity of PTL and 
tulipane. All of PGA, CII and MEC1 cell lines ware previously established from 
peripheral blood, refer to Table 15. 
PGA, CII and MEC1 cell lines were maintained in RPMI1640 medium supplemented 
with 10% Fetal Bovine Serum (FBS) and [+]L-Glutamine. Cells were always kept in 
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small sample flask and leaved into the conventional culture incubator in 37 °C and 
with the volume fraction of 5% CO2. 
4.4.2 Biological Experimental Work 
Cells were quantified using a haemocytometer. Cells were seeded onto a 96 well 
culture plate in triplicate and compounds dissolved in DMSO were added. Cells were 
plated at 10 000 cells per well and incubated with each compound for 24 hours. For 
each compound concentration the volume of DMSO used were adjusted so that the 
concentration of DMSO was the same for each drug treatment.  
4.4.3 Flow cytometric analysis of cell death 
Following 24 hours of treatment, PI (Propidium Iodide) was added to cell media. PI 
+ve cells were measured using BD Accuri C6 Flow Cytometer. Data was expressed 
either as percentage of PI + ve cells or as the surviving fractions (PI -ve) relative to 




(1aR, 7aS, 10aS, 10bS, E)-1a,5,7a-Trimethyl-8-methylene-2,3,6,7,7a,8,10a,10b-
octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH):one: Compound 1 
1
H NMR (300 MHz, CDCl3) δ 6.35 (d, J = 3.7, 1H, C=CH2), 5.64 (d, 
J = 3.3, 1H, C=CH2), 5.23 (dd, J = 12.0, 2.4, 1H, CH3C=CH), 3.88 (t, J = 8.6, 1H, 
CHOCO), 2.93 to 2.68 (m, 2H), 2.51 to 2.34 (m, 2H), 2.21 to 2.12 (m, 3H), 1.81 to 
1.71 (m, 4H), 1.37 to 1.14 (m, 5H).; 
13
C NMR (100 MHz, CDCl3) δ 169.24 (C=O), 
139.26 (C=CH2), 134.60 (CH=CCH3); 125.30 (CH=CCH3), 121.23 (C=CH2), 82.45 
(CHOCO), 66.41 (CH, epoxide moiety), 61.52 (CH3CO), 47.69 (CH2CCH), 41.24 
(CH2CHCCH2), 36.38 (OCCH2), 30.67 (CH2=CCHCH2), 24.16 (CH2CH2CO), 17.29 
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(CH3C-O), 16.96 (CH3CCHCH2); IR (neat) cm-1 1753 cm
-1
 (C=O); MS (EI+) m/z 
([M+ Na]
+
)= 271; mp= 144-146 °C (colourless crystalline solid). 
Literature data of Parthenolide: 
1
H NMR (CDCl3, 300 MHz) δ 6.34 (d, J = 3.6, 1H, 
C=CH2), 5.62 (d, J = 3.0, 1H, C=CH2), 5.21 (dd, J = 2.7, 12.0, 1H, CH3C=CH), 3.86 
(t, J = 8.4, 1H, CHOCO), 2.79 (d, J = 9.0, 1H, CH, epoxide moiety), 2.74 to 2.82 (m, 
1H, CHC=CH2), 2.32 to 2.49 (m, 2H), 2.11 to 2.21 (m, 4H), 1.72 (s, 3H, 
CH2CHCCH3), 1.70 to 1.77 (m, 1H, CH3CCH2CH2), 1.31 (s, 3H, CH3CO), 1.20 to 
1.28 (m, 1H, CH2CHO); 
13
C NMR (CDCl3, 75.5 MHz) δ 169.3 (C=O), 139.2 
(C=CH2), 134.6 (CH=CCH3); 125.3 (CH=CCH3), 121.3 (C=CH2), 82.4 (CHOCO), 
66.4 (CH, epoxide moiety), 61.5 (CH3CO), 47.7 (CH2CCH), 41.2 (CH2CHCCH2), 
36.3 (OCCH2), 30.6 (CH2=CCHCH2), 24.1 (CH2CH2CO), 17.3 (CH3CO), 16.9 
(CH3CCHCH2); mp=145-146 °C. 
 
4.6 Tulipane Derivatives 
3-((Prop-2-yn-1-ylamino) methyl) dihydrofuran-2(3H)-one: Compound 6a. 
Propargylamine (2.45 mmol, 0.157 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 6a was obtained as clear oil (60 %, 0.186 g). 
1
H NMR δH (400 
MHz, CDCl3) δ4.35 (1H, td, J = 8.8, 2.4, CH2OC=O), 4.25 to 4.28 (1H, m, 
CH2OC=O), 3.50 (2H, s, NHCH2), 3.00 to 2.90 (2H, dd, J = 11.6, 6.0, CHCH2N), 
2.70 to 2.77 (1H, m, CH), 2.37 to 2.47(1H, m, CH2CH2CH), 2.27 (1H, s, CH), 2.08 to 
2.12 (1H, m, CH2CH2CH), 1.83 (1H, NH). 
13
C NMR (100 MHz, CDCl3) δ26.8 
(CH2CH2CH), 38.3 (CH2NH), 39.6 (CH), 48.3 (NCH2CH), 66.9 (CH2OC=O), 71.7 
(CH), 81.7 (C), 178.6 (C=O); IR (neat) cm
-1
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3-((Benzylamino) methyl) dihydrofuran-2(3H)-one: Compound 6b. 
 Benzylamine (2.04 mmol, 0.222 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 6b was obtained as yellow oil (61.5 %, 0.257 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ7.30 (4H, d, J = 4.4, Ph), 7.22 to 7.15 (1H, m, Ph), 4.29 (1H, td, J 
= 8.8, 2.8 CH2OC=O), 4.15 (1H, td, J = 6.8, 9.2 CH2OC=O), 3.80 (2H, d, J = 2.8, Ph-
CH2), 2.80 to 2.90 (2H, m, CHCH2N), 2.70 (1H, m, CH), 2.25 to 2.33 (1H, m, 
CH2CH2CH), 2.09 to 2.12 (1H, m, CH2CH2CH), 1.85 (1H, NH). 
13
C NMR (100 MHz, 
CDCl3) δ26.8 (CH2CH2CH), 39.8 (CH), 48.9 (NCH2CH), 53.9 (NHCH2Ph), 66.9 
(CH2OC=O), 127.0 (Ph), 128.1 (Ph), 128.4 (Ph), 140.1 (C),178.9 (C=O); IR (neat) 
cm
-1




3-((Methyl (propyl) amino) methyl) dihydrofuran-2(3H)-one: Compound 7a 
 N-methylpropylamine (2.45 mmol, 0.25 mL) was added into the 
stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and 
using the general procedure A, 7a was obtained as yellow oil (78 %, 0.272 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ 4.39 (td, J = 8.8, 3.3, 1H, , CH2-O-C=O), 4.24 (td, J = 
9.2, 7.0, 1H, , CH2OC=O), 2.84 to 2.69 (m, 2H), 2.60 to 2.51 (m, 1H), 2.49 to 2.27 (m, 
3H), 2.26 (s, 3H, CH3N), 2.16 (td, J = 16.5, 6.5, 1H), 1.56 to 1.41 (m, 2H, 
CH2CH2CH3), 0.90 (t, J = 7.4, 3H, CH3). 
13
C NMR (100MHz, CDCl3) 11.7 (CH3), 
20.3 (CH2CH2CH3), 28.1 (CH2CH2CH), 38.5 (CH), 42.3 (CH3N), 57.8 
(CH2OHCH2N), 59.8 (NCH2CH2), 66.8 (CHOC=O), 178.8 (C=O); IR (Neat) cm
-1 
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3-((Isopropyl (methyl) amino) methyl) dihydrofuran-2(3H)-one: Compound 7b. 
 N-Isopropylmethylamine (2.45 mmol, 0.225 mL) was added into the 
stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and 
using the general procedure A, 7b was obtained as yellow oil (32 %, 0.112 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ4.40 (1H, td, J = 3.6, 8.8, CH2OC=O), 4.25 (1H, td, J = 
7.2, 9.2, CH2OC=O), 2.80 to 2.90 (2H), 2.65 to 2.75 (1H, m), 2.55 (1H, dd, J = 3.2, 
12.8, CH2OHCH2N), 2.40 to 2.45 (1H, m, CH2CH2CH), 2.25 (3H, s, CH3N), 2.1 to 
2.20 (1H, m, CH2CH2CH), 1.05 (6H, dd, J = 6.8, 4, CHCH3). 
13
C NMR (100 MHz, 
CDCl3) δ 17.0 (CHCH3), 18.5 (CHCH3), 27.7 (CH2CH2CH), 37.3 (CH3N), 28.9 (CH), 
(CH2CH2CH), 38.8 (CH), 58.6 (CH2OHCH2N), 54.1 (NCHCH3), 66.9 (CH2OC=O), 
179.0 (C=O); IR (neat) cm
-1




3-(Pyrrolidin-1-ylmethyl) dihydrofuran-2(3H)-one: Compound 8a 
  Pyrrolidine (2.45 mmol, 0.28 mL) was added into the stirred solution 
of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the general 
procedure A, 8a was obtained as yellow oil (86 %, 0.295 g). 
1
H NMR δH (400 MHz, 
CDCl3) δ4.35 (1H, td, J = 8.8, 3.2, CH2OC=O), 4.20 (1H, , td, J = 9.6, 7.2, 
CH2OC=O), 2.90 (dd, 2H, J = 11.6, 3.6, CH2OHCH2N), 2.65 to 2.75 (m, 2 H), 2.55 to 
2.62 (m, 2H), 2.31 (m, 1H), 1.76 to 1.82 (m, 4H) 
13
C NMR(100MHz, CDCl3) 23.4 
(CH2CH2CH2), 23.6 (CH2CH2CH2), 28.1 (CH2CH2CH), 39.7 (CH), 53.9 (CH2N), 54.4 
(CH2N), 56.3 (CH2OHCH2N), 66.8 (CH2OC=O), 178.6 (C=O); IR (Neat) cm
-1 
1763 




3-(Piperidin-1-ylmethyl) dihydrofuran-2(3H)-one: Compound 8b 
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 Piperidine (2.45 mmol, 0.242 mL) was added into the stirred solution 
of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the general 
procedure A, 8b was obtained as pale yellow oil (91 %, 0.339 g). 
1
H NMR δH (400 
MHz, CDCl3) δ 4.30 (td, J = 8.8, 3.3, 1H, CH2OC=O), 4.14 (td, J = 9.1, 6.9, 1H, 
CH2OC=O), 2.79 to 2.62 (m, 2H), 2.51 to 2.26 (m, 6H), 2.17 to 2.03 (m, 1H), 1.50 to 
1.58 (4H, m, NCH2CH2CH2), 1.35 to 1.42 (2H, m, NCH2CH2CH2).; 
13
C NMR (100 
MHz, CDCl3) δ 24.2 (CH2CH2CH2), 26.0 (CH2CH2CH2), 28.2 (CH2CH2CH), 38.2 
(CH); 54.7 (CH2CH2N), 59.1 (CH2OHCH2N), 66.8 (CH2OC=O), 178.8 (C=O); IR 
(neat) cm
-1




3-(Morpholinomethyl) dihydrofuran-2(3H)-one: Compound 8c 
 Morpholine (2.45 mmol, 0.214 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, Compound 8c was obtained as pale yellow oil (81 %, 0.307 g). 
1
H NMR δH (400 MHz, CDCl3) δ 4.40 (td, J = 8.8, 3.2, 1H, CH2OC=O), 4.25 (td, J = 
9.2, 7.0, 1H, CH2OC=O), 3.77 to 3.66 (m, 4H), 2.90 to 2.70 (m, 2H), 2.65 to 2.38 (m, 
6H), 2.21 (ddd, J = 18.1, 12.9, 9.2, 1H, CH2CH2CH).; 
13
C NMR (100 MHz, CDCl3) δ 
27.9 (CH2CH2CH), 38.0 (CH); 53.8 (CH2CH2N), 58.6 (CH2OHCH2N), 66.6 
(CH2OCH2), 66.8 (CH2OCH2), 66.9 (CH2OC=O), 178.8 (C=O); IR (neat) cm
-1
 1760 




3-((4-Methylpiperazin-1-yl) methyl) dihydrofuran-2(3H)-one: Compound 8d 
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1-Methylpiperazine (2.45 mmol, 0.272 mL) was added into the 
stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and 
using the general procedure A, 8d was obtained as yellow oil (61 %, 0.245 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ4.38 (1H, td, J = 8.8, 3.2 CH2OC=O), 4.22 (1H, td, J = 
4.3, 8.8 CH2OC=O), 2.85 (1H, dd, J = 12.4, 4.4, CH2OHCH2N), 2.8 to 2.7 (1H, m, 
CH), 2.31 to 2.69 (10 H, m), 2.31 (3H, s, NCH3), 2.10 to 2.23 (1H, m). 
13
C NMR (100 
MHz, CDCl3) δ28.1 (CH2CH2CH), 38.1 (CH), 46.0 (CH3), 53.3 (CH2CH2N), 55.1 
(CH2CH2N), 58.3 (NCH2CH), 66.8 (CH2OC=O), 178.7 (C=O); IR (neat) cm
-1
 1750 




3-((Dimethylamino) methyl) dihydrofuran-2(3H)-one: Compound 9a 
Dimethylamine (2.45 mmol, 0.225 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 9a was obtained as yellow oil (70 %, 0.204 g). 
1
H NMR δH (400 
MHz, CDCl3) δ4.11 (1H, td, J = 2.4, 8.8, CH2OC=O), 3.95 (1H, td, J = 9.0, 6.8, 
CH2OC=O), 2.35 to 2.5 (2H, m), 2.10 to 2.18 (2H, m), 2.05 (6H, s, CH3N), 1.33 to 
1.38(1H, m). 
13
C NMR (100 MHz, CDCl3) δ27.7 (CH2CH2CH), 38.1 (CH), 45.1 
(CH3-N), 45.3 (CH3-N), 59.5 (CH2OHCH2N), 66.5 (CH2OC=O), 178.3 (C=O); IR 
(neat) cm
-1




3-((Dipropylamino) methyl) dihydrofuran-2(3H)-one: Compound 9b 
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 Dipropylamine (2.45 mmol, 0.336 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 9b was obtained as yellow oil (35 %, 0.141 g). 
1
H NMR δH (400 
MHz, CDCl3) δ4.40 (1H, td, J = 8.8, 3.6, CH2OC=O), 4.21 (td, J = 8.8, 6.8, 1H, 
CH2OC=O), 2.92 (1H, dd, J = 12.8, 4, CH2OHCH2N), 2.70 to 2.75 (1H, m, CH), 2.55 
(1H, dd, J = 10, 3.2, CH2OHCH2N), 2.32 to 2.55 (5H, m), 2.18 to 2.25 (1H, m), 1.40 
to 1.49 (4H, m, CH2CH2CH3), 0.85 (6H, t, J = 7.2, CH2CH2CH3); 
13
C NMR (100 
MHz, CDCl3) δ 11.8 (CH2CH3), 20.2 (CH2CH2CH3), 28.1 (CH2CH2CH), 38.8(CH), 
54.6(CHCH2N), 56.1 (CH2CH2N), 66.9 (CH2OC=O), 179.0 (C=O); IR (neat) cm
-1
 




(2S)-2-(((2-Oxotetrahydrofuran-3-yl) methyl) amino) propanoic acid: Compound 
10a. 
L-Alaine (2.04 mmol, 0.182 g) was added into the stirred solution 
of 1.2eq tulipane (0.215 mL, 2.45 mmol) in 15 ml methanol and water mixture and 
using the general procedure B, mixture of diastereoisomers of 10a was obtained as 
colourless crystalline solid (33 %, 0.126 g). A crude analysis of the diastereomeric 
ratio of two diastereoisomers: 10a-1 and 10a-2 by proton NMR, was estimated around 
1:1. 
1
H NMR δH (400 MHz, D2O) δ4.42 (1H, td, J = 4, 8.4, CH2OC=O), 4.28 (1H, td, 
J = 6.4, 8.8, CH2OC=O), 3.55 to 3.75 (1H, m), 3.05 to 3.40 (3H, m), 2.45 to 2.51 (1 H, 
m, CH2CH2CH), 2.08 to 2.15 (1H, m, CH2CH2CH), 1.42 (3H, d, J = 9, CH3). 
13
C 
NMR (100 MHz, D2O) 14.8 (CH3), 14.9 (CH3), 26.5 (CH2CH2CH), 26.7 
(CH2CH2CH), 36.9 (CH2CH2CH), 37.1 (CH2CH2CH), 45.7 (CHCH2N), 58.4 (CH-
CH3), 59.2 (CHCH3), 66.2 (CH2CH2O), 174.4 (C=O/Carboxylic acid), 179.4 (C=O), 
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179.7 (C=O); mp=253-255 °C; IR (neat) cm
-1





2-(((2-Oxotetrahydrofuran-3-yl) methyl) amino) acetic acid: Compound 10b 
Glycine (2.04 mmol, 0.153 g) was added into the stirred solution 
of 1.2eq tulipane (0.215 mL, 2.45 mmol) in 15 ml methanol and water mixture and 
using the general procedure B, 10b was obtained as colourless crystalline solid (20 %, 
0.071 g). 
1
H NMR δH (400 MHz, D2O) δ4.45 (1H, td, J = 2.8, 8.8, CH2OC=O), 4.25 
(1H, td, J = 7.2, 2.4, CH2OC=O), 3.60 (2H, s), 3.37 (1H, dd, J = 7.6, 12.8, CHCH2N), 
3.15 to 3.30 (2H, m), 2.15 to 2.45 (2H, m, CH2CH2CH). 
13
C NMR (100 MHz, D2O) 
26.6 (CH2CH2CH), 36.8 (CH), 46.9 (CHCH2N), 49.5 (CH2CO2H), 68.5 (CH2CH2O), 
170.8 (C=O/Carboxylic acid), 179.6 (C=O); mp=225-227°C; IR (neat) cm
-1
 3333 




(2S)-3-Methyl-2-(((2-oxotetrahydrofuran-3-yl) methyl) amino) butanoic acid: 
Compound 10c 
L-valine (2.04 mmol, 0.239 g) was added into the stirred solution 
of 1.2eq tulipane (0.215 mL, 2.45 mmol) in 15 ml methanol and water mixture. Using 
the general procedure B, mixture of diastereoisomers of 10c was obtained as 
colourless crystalline solid (13 %, 0.069 g). A crude analysis of the diastereomeric 
ratio of two diastereoisomers 10c-1 and 10c-2 by proton NMR was estimated around 
37:63 or 63:37. 
1
H NMR δH (400 MHz, D2O) δ4.45 (1H, td, J = 4.0, 8.4, CH2OC=O), 
4.28 (1H, td, J = 6.4, 8.8, CH2OC=O), 3.40 to 3.45 (1H, dd, J = 4.0) 3.15 to 3.35 (3H, 
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m), 2.46 to 2.52 (1H, m), 2.01 to 2.22 (3 H, m), 0.93 (6H, dd, J = 6.8, 14.8, CHCH3). 
13
C NMR (100 MHz, D2O) 17.1 (CH3), 17.3 (CH3), 17.9 (CH3), 18.0 (CH3), 26.6 
(CH2CH2CH), 26.8 (CH2CH2CH), 29.0 (CHCHCH3), 29.2 (CHCHCH3), 47.2 
(CH2CH2CH), 47.6 (NCH2CH), 60.3 (CHCH2N), 68.6 (CH2CH2O), 69.1 (CHCO2H), 
172.2 (C=O/Carboxylic acid), 172.3 (C=O/Carboxylic acid), 179.9 (C=O), 180.0 
(C=O); mp=265-266 °C; IR (neat) cm
-1





3-(((2-Hydroxyethyl)thio)methyl)dihydrofuran-2(3H)-one: Compound 11a 
 2-Mercaptoethanol (2.45 mmol, 0.172 mL) was added into the 
stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and 
using the general procedure A, 11a was obtained as yellow oil (78 %, 0.28 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ4.41 (1H, td, J = 2.8, 8.8, CH2OC=O), 4.25 (1H, td, J = 
9.6, 6.8, CH2OC=O), 3.75 (2H, t, J = 6.2, CH2CH2S), 3.05 (1H, OH), 2.91 (1H, dd, J 
= 13.2, 4.4, CH2OHCH2N), 2.65 to 2.82 (3H, m), 2.25 to 2.50 (2H, m, CH2CH2CH). 
13
C NMR (100 MHz, CDCl3) δ27.8 (CH2CH2CH), 32.0 (CH2OHCH2N), 35.5 
(CH2CH2S), 40.0 (CH), 61.0 (CH2OH), 66.9 (CH2OC=O), 178.2 (C=O); IR (neat) cm
-
1




3-((Benzylthio) methyl) dihydrofuran-2(3H)-one: Compound 11b 
 Benzylamine (2.04 mmol, 0.222 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 11b was obtained as yellow oil (84.8 %, 0.384 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ7.28 (4H, d, J = 4.4, Ph), 7.20 (1H, m, Ph), 4.27 (1H, td, J = 8.8, 
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2.8, CH2OC=O), 4.10 (1H, td, J = 6.8, 9.2, CH2OC=O), 3.70 (2H, d, J = 2.8, PhCH2), 
2.90 (2H, dd J = 4.0, 13.2 CHCH2N), 2.70 (1H, m, CH), 2.30 to 2.40 (1H, m), 1.97 to 
2.10 (1H, m). 
13
C NMR (100 MHz, CDCl3) δ28.0 (CH2CH2CH), 31.8 (SCH2CH), 
37.0 (SCH2Ph), 39.7 (CH), 66.7 (CH2OC=O), 127.2 (Ph), 128.9 (Ph), 129.1 (Ph), 
138.0 (C), 177.8 (C=O); IR (neat) cm
-1





3-(((2-Hydroxyethyl) amino) methyl) dihydrofuran-2(3H)-one: Compound 12a 
 Ethanolamine (2.45 mmol, 0.15 mL) was added into the stirred 
solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and using the 
general procedure A, 12a was obtained as yellow oil (71 %, 0.232 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ4.40 (1H, td, J = 11.6, 2.8 CH2OC=O), 4.31 (1H, td, J = 6.8, 9.2 
CH2OC=O), 3.65 (2H, t, J = 5.2 CH2CH2OH),2.95 (1H, dd, J = 12, 6.4, CHCH2N), 
2.75 to 2.92 (4H, m), 2.35 to 2.40 (1H, m), 2.05 to 2.20 (1H, m). 
13
C NMR (100 MHz, 
CDCl3) δ26.9 (CH2CH2CH), 39.6 (CH), 49.2 (CHCH2), 51.3 (CH2CH2N), 60.7 
(CH2CH2OH), 66.9 (CH2OC=O), 179.0 (C=O); IR (neat) cm
-1





3-(((2-Hydroxyethyl) (methyl) amino) methyl) dihydrofuran-2(3H)-one: 
Compound 12b 
 
N-Methylethanolamine (2.45 mmol, 0.19 mL) was added into 
the stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) 
in 15 mL methanol and using the general procedure A, 12b was obtained as pale 
yellow oil (91 %, 0.321 g). 
1
H NMR δH (400 MHz, CDCl3) δ4.38 (1H, td, J = 8.8, 2.8, 
CH2OC=O), 4.24 (1H, td, J = 9.6, 2.8 CH2OC=O), 3.60 (2H, t, J = 5.2, CH2OH), 2.93 
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(2H, dd, J = 12.4, 5.2, CHCH2N), 2.70 to 2.80 (1H, m, CH), 2. 55 to 2.65 (2H, m, 
CH2CH2OH), 2.41 to 2.49 (1H, m), 2.32 (3H, s, Methyl group), 2.10 to 2.15 (1H, m); 
13
C NMR (100 MHz, CDCl3) δC 28 (CH2CH2CH), 38.3 (CH3), 41.9 (CH), 58.0 
(CH2N), 58.5 (CH2OHCH2N), 58.9 (CH2OH), 66.7 (CH2OC=O), 178.4 (C=O); IR 
(Neat) cm
-1 




3-((Ethyl (2-hydroxyethyl) amino) methyl) dihydrofuran-2(3H)-one: Compound 
12c 
 2-(Ethylamino) ethanol (2.45 mmol, 0.239 mL) was added into 
the stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol 
and using the general procedure A, 12c was obtained as yellow oil (61 %, 0.232 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ 4.37 (1H, td, J = 8.8, 3.6 CH2OC=O), 4.24 (1H, td, J = 
6.8, 9.2, CH2OC=O), 3.57 (2H, t, J = 5.6 CH2CH2OH), 3.33 (1H, s, OH), 2.95 (1H, dd, 
J = 13.2, 5.2, CHCH2N), 2.80 to 2.70 (1H, m, CH), 2.71 to 2.55 (5H, m), 2.50 to 2.4 0 
(1H, m), 1.99 to 2.15 (1H, m), 1.05 (3H, t, J = 7). 
13
C NMR (100 MHz, CDCl3) δ11.4 
(CH3), 28.0 (CH2CH2CH), 38.3 (CH), 47.5 (CH3CH2), 53.9 (CHCH2N), 55.0 
(CH2CH2N), 58.7 (CH2CH2OH), 66.7 (CH2OC=O), 178.7 (C=O); IR (neat) cm
-1
 1760 




3-(((2-Methoxyethyl) amino) methyl) dihydrofuran-2(3H)-one: Compound 12d 
2-Methoxyethylamine (2.45 mmol, 0.18 mL) was added into the 
stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL methanol and 
using the general procedure A, 12d was obtained as clear oil (81 %, 0.291 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ4.37 (1H, td, J = 8.8, 2.8 CH2OC=O), 4.23 (1H, td, J = 
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6.8, 9.6 CH2OC=O), 3.48 (2H, t, J = 5.2 MeOCH2), 3.34 (3H, s, CH3), 2.95 (1H, dd, J 
= 12, 5.6, CHCH2N), 2.72 to 2.88 (4H, m), 2.35 to 2.45 (1H, m, CH2CH2CH), 2.06 to 
2.18 (1H, m, CH2CH2CH), 1.95 to 1.99 (1H, m, NH). 
13
C NMR (100 MHz, CDCl3) 
δ26.7 (CH2CH2CH), 39.6 (CH), 49.1 (NCH2), 49.4 (CHCH2N), 58.5 (CH3), 66.7 
(CH2OC=O), 71.7 (CH2OMe), 178.6 (C=O); IR (neat) cm
-1







(2-Methoxyethyl) methylamine (2.45 mmol, 0.266 mL) was added 
into the stirred solution of tulipane (200 mg, 0.179 mL, 2.04 mmol) in 15 mL 
methanol, 12e was obtained as clear oil (48 %, 0.183 g). 
1
H NMR δH (400 MHz, 
CDCl3) δ4.35 (1H, td, J = 3.6, 8.8 CH2OC=O), 4.21 (1H, td, J = 9.2, 6.8, CH2OC=O), 
3.45 to 3.55 (2H, m, NCH2CH2O), 3.35 (3H, s, OCH3), 2.90 (1H, dd, J = 12.8, 4.4, 
CH2OHCH2N), 2.65 to 2.80 (2H, m), 2.51 to 2.65 (2H, m), 2.40 to 2.45 (1H, m), 2.30 
(3H, s, NCH3), 2.15 to 2.20 (1H, m). 
13
C NMR (100 MHz, CDCl3) δ28.1 
(CH2CH2CH), 38.4 (CH), 42.9 (CH3N), 56.9 (NCH2CH2O), 58.0 (CH2OHCH2N), 
58.8 (NCH3), 66.8 (CH2OC=O), 70.5 (NCH2CH2O), 178.3 (C=O); IR (neat) cm
-1
 




N-(2-Hydroxyethyl)-N-((2-oxotetrahydrofuran-3-yl) methyl) acetamide: 
Compound 13a 
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Acetic Anhydride (1.06 mmol 0.1 mL) was added into the stirred 
solution of Compound 12a (0.141 g, 0.9 mmol) in 15 mL DCM and using the general 
procedure C, 13a was obtained as yellow oil (51 %, 0.092 g). 
1
H NMR δH (400 MHz, 
CDCl3) δ 4.40 (1H, td, J = 8.4, 4.0, CH2OC=O), 4.25 (1H, td, J = 6.4, 8.8, 
CH2OC=O), 3.40 to 3.95 (7H, m), 2.91 to 3.05 (1H, m), 1.95 to 2.15 (1H, m), 2.20 
(3H, s). 
13
C NMR (100 MHz, CDCl3) δ 21.9 (CH3), 27.6 (CH2CH2CH), 38.9 (CH), 
46.2 (CH2CH), 52.0 (CH2CH2N), 60.2 (CH2OH), 67.0 (CH2OC=O), 172.4 
(C=O/amide), 178.8 (C=O); IR (neat) cm
-1
 1759 and 1617 (C=O); MS (EI+) m/z 
([M+Na]
 +
) = 224. 
 
N-(2-Methoxyethyl)-N-((2-oxotetrahydrofuran-3-yl) methyl) acetamide: 
Compound 13b 
 Acetyl chloride (1.6 mmol 0.115ml) was added into the stirred 
solution of Compound 12d (0.141 g, 1.3 mmol) in 15 mL DCM and using the general 
procedure C, 13b was obtained as clear oil (48 %, 0.134 g). 
1
H NMR δH (400 MHz, 
CDCl3) δ4.37 (1H, td, J = 8.8, 2.8, CH2OC=O), 4.23 (1H, td, J = 6.8, 9.6, CH2OC=O), 
3.48 (2H, t, J = 5.2, MeOCH2), 3.34 (3H, s, CH3), 2.95 (1H, dd, J = 12, 5.6, 
CHCH2N), 2.72 to 2.88 (4H, m), 2.35 to 2.45 (1H, m, CH2CH2CH), 2.06 to 2.18 (1H, 
m, CH2CH2CH), 1.95 to 2.00 (1H, m, NH). 
13
C NMR (100 MHz, CDCl3) δ21.7 (CH3), 
27.3 (CH2CH2CH), 39.0 (CH), 45.7 (CH2CH), 49.2 (CH2CH2N), 59.0 (CH3O), 66.8 
(CH2OC=O), 70.6 (CH2O), 171.8 (C=O/amide), 178.2 (C=O); IR (neat) cm
-1
 1761 
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4.7 Parthenolide Derivatives 
(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8 ((propylamino)methyl)-
2,3,6,7,7a,8,10a,10b octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14a 
 N-Methylpropylamine (0.48 mmol, 0.05 mL) was added 
into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and 
using the general procedure A, 14a was obtained as colourless solid (78.6 %, 0.101 g). 
1
H NMR δH (400 MHz, CDCl3) δ5.20 (1H, dd, J = 12, 2, CH=C), 3.82 (1H, t, J = 9, 
CH-O-CO), 2.65 to 2.85 (3H, m), 2.01 to 2.50 (13H, m), 1.70 (1H, s, CH=CCH3), 
1.55 to 1.65 (1H, m), 1.47 (2H, dd, J = 7.2, 14.8), 1.30 (3H, s), 1.20 to 1.25 (1H, m), 
0.9 (3H, t, J = 7.4, CH3-CH2).
 13
C NMR (100 MHz, CDCl3): δ11.8, 17.0, 17.2, 20.6, 
24.1, 30.0, 36.7, 41.1, 42.6, 46.5, 47.9, 56.3, 60.5, 61.5, 66.6, 82.2, 124.9, 134.8, 
176.7.; mp= 117-119 °C; [α]
18
D =-23.2° (c =1, CDCl3); IR (neat) cm
-1
 1769 (C=O).; 




(1aR, 7aS, 8R, 10aS, 10bS, E)-8-((Isopropyl(methyl)amino)methyl)-1a,5-
dimethyl-2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one: Compound 14b 
 N-Isopropylmethylamine (0.48 mmol, 0.05 mL) was added 
into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and 
using the general procedure A, 14b was obtained as colourless solid (36 %, 0.046 g). 
1
H NMR δH (400 MHz, CDCl3) δ5.21 (1H, dd, J = 12, 2, CH=C), 3.82 (1H, t, J = 8.8, 
CHOCO), 2.65 to 2.85 (4H, m), 2.21 to 2.50 (11H, m), 1.70 (3H, s, CH=CCH3), 1.55 
to 1.65 (1H, m), 1.3 (3H, s, NCH3), 1.19 to 1.29 (2H, m,), 0.98 to 1.10 (5H, m).
 13
C 
NMR (100 MHz, CDCl3): 17.0, 17.2, 17.8, 17.9, 24.1, 30.1, 36.7, 37.3, 41.1, 46.6, 
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47.8, 52.0, 54.7, 61.5, 66.7, 82.2, 124.9, 134.8, 176.9.; mp= 111-113 °C; [α]
18
D =-12.4° 
(c =1, CDCl3); IR (neat) cm
-1




(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8-(pyrrolidin-1-ylmethyl)-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14c 
 Pyrrolidine (0.48 mmol, 0.04 mL) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the general 
procedure A, 14c was obtained as colourless solid (83 %, 0.106 g). 
1
H NMR δH (400 
MHz, CDCl3) δ 5.22 (1H, d, J = 12, 2, CH=C), 3.81 (1H, t, J = 9, CHOCO), 2.89 (2H, 
qd, J = 4.8, 13.2, 31.2, CH2CH2CH2), 2.74 (1H, d, J = 8.8, OCHCHOCO), 2.50 to 2.6 
0 (4H, m), 2.02 to 2.45 (8H, m), 1.58 to 1.80 (8H, m), 1.31 (3H, s), 1.20 to 1.25 (1H, 
m).
 13
C NMR (100 MHz, CDCl3): δ17.0, 17.2, 23.8, 24.1, 30.0, 36.7, 41.1, 47.4, 47.6, 
53.7, 54.8, 61.5, 66.6, 82.1, 125.0, 134.8, 176.6.; mp= 128-129 °C; [α]
18
D =-16.4° (c 
=1, CDCl3); IR (neat) cm
-1




(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8-(piperidin-1-ylmethyl)-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14d 
 Piperidine (0.48 mmol, 0.047 mL) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the general 
procedure A, 14d was obtained as colourless solid (83 %, 0.106 g). 
1
H NMR δH (400 
MHz, CDCl3) δ 5.20 (1H, dd, J = 12.0, 2.0, CH=C), 3.75 (1H, t, J = 9, CHOCO), 2.75 
(2H, td, J = 4.8, 9.2, CH2CH2CH2), 2.60 (1H, dd, J = 5.6, 13.2, CHCH2N), 2.35 to 
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2.51 (6H, m), 2.00 to 2.30 (6H, m), 1.71 (3H, s), 1.50 to 1.68 (5H, m), 1.38 to 1.48 
(2H, m), 1.32 (3H, s), 1.22 to 1.26 (1H, m).
 13
C NMR (100 MHz, CDCl3): δ17.1, 17.2, 
24.1, 14.2, 26.1, 30.1, 36.7, 41.2, 46.1, 48.2, 55.1, 57.5, 61.4, 66.7, 82.3, 124.7, 134.9, 
176.8.; mp= 140-141°C; [α]
18
D =-4.8° (c =1, CDCl3);  IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8-(morpholinomethyl)-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14e 
 Morpholine (0.48 mmol, 0.042 mL) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the general 
procedure A, 14e was obtained as colourless solid (83.5 %, 0.112 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ5.20 (1H, dd, J = 2.0, 12.0, CH=C), 3.85 (1H, t, J = 9.0, 
CHOCO), 3.67(3H, t, J = 4.6, CH2CH2O), 2.68 to 2.84 (3H, m), 2.50 (3H, t, J = 4.2, 
CH2CH2O ), 2.00 to 2.48 (9H, m), 1.70 (3H, s), 1.61 to 1.68 (1H, m), 1.31 (3H, s), 
1.19 to 1.27 (1H, m). 
13
C NMR (100 MHz, CDCl3): δ17.0, 17.2, 24.1, 29.7, 30.0, 36.6, 
41.2, 46.1, 48.0, 54.3, 56.9, 61.5, 66.6, 67.0, 82.2, 124.9, 134.7, 176.4.; mp= 172-
173 °C; [α]
18
D =-2.8° (c =1, CDCl3); IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-8-((Dipropylamino)methyl)-1a,5-Dimethyl-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14f 
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 Dipropylamine (0.48 mmol, 0.066 mL) was added into the 
stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the 
general procedure A,  14f was obtained as colourless solid (43 %, 0.06 g). 
1
H NMR 
δH (400 MHz, CDCl3) δ5.21 (1H, dd, J = 2.0, 12.0, CH=C), 3.85 (1H, t, J = 9.0, 
CHOCO), 2.71 to 2.91 (2H, m), 2.05 to 2.50 (10H, m), 1.70 (3H, s), 1.21 to 1.68 (12H, 
m), 0.85 to 0.95 (6H, m). 
13
C NMR (100 MHz, CDCl3): 11.9, 17.0, 20.1, 24.1, 30.1, 
33.4, 36.7, 41.2, 46.8, 48.2, 53.7, 56.3, 66.7, 82.2, 124.9, 134.8, 176.8, 207.0.; mp= 
166-167 °C; [α]
18
D =-6° (c =1, CDCl3); IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-8-((Benzylamino)methyl)-1a,5-Dimethyl-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound14g 
 Benzylamine (0.48 mmol, 0.052 mL) was added into the 
stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the 
general procedure A, 14g was obtained as pale yellow solid (75 %, 0.107 g). 
1
H NMR 
δH (400 MHz, CDCl3) δ7.20 to 7.35 (5H, m), 5.15 (1H, dd, J = 2, 12.4, CH=C), 3.74 
to 3.90 (3H, m), 3.01 (1H, dd, J = 12.0, 3.6, CHCH2N), 2.70 to 2.77 (2H, m), 2.01 to 
2.47 (6H, m), 1.92 to 1.99 (2H, m), 1.80 (1H, dd, J = 14.8, 6.4, CH2CH2C), 1.67 (3H, 
s), 1.55 to 1.68 (1H, m), 1.28 (3H, s), 1.16 to 1.27 (1H, m). 
13
C NMR (100 MHz, 
CDCl3): δ16.9, 17.2, 24.1, 30.0, 36.6, 41.0, 46.0, 46.5, 48.2, 53.9, 61.5, 66.4, 82.6, 
125.1, 127.0, 128.1, 128.4, 134.6, 140.1, 176.7. mp= 160-161 °C; [α]
18
D =-15.2° (c =1, 
CDCl3); IR (neat) cm
-1
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(1aR, 7aS, 8S, 10aS, 10bS, E)-8-((Benzylthio)methyl)-1a,5-Dimethyl-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 14h 
 Benzyl Mercapton (0.48 mmol, 0.056 mL) was added 
into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and 
using the general procedure A, 14h was obtained as yellow semi-solid (56 %, 0.084 g). 
1
H NMR δH (400 MHz, CDCl3) δ7.20 to 7.40 (5H, m), 5.15 (1H, dd, J = 2.0, 12.0, 
CH=C), 3.74 to 3.90 (3H, m), 3.01 (1H, dd, J = 9.8, 3.6, CHCH2N), 2.7 0 to 2.77 (2H, 
m), 2.00 to 2.47 (6H, m), 1.89 to 2.02 (2H, m), 1.83 (H, dd, J = 14.8, 6.4, CH2CH2C), 
1.67 (3H, s), 1.55 to 1.68 (1H, m), 1.28 (3H, s), 1.16 to 1.28 (1H, m). 
13
C NMR (100 
MHz, CDCl3): δ17.1, 24.1, 29.8, 34.7, 36.8, 37.8, 40.9, 47.7, 48.0, 50.3, 61.6, 66.3, 
82.6, 124.5, 125.1, 128.6, 129.2, 134.5, 140.1, 175.6.; [α]
18
D =+13.6° (c =1, CDCl3); 
IR (neat) cm
-1




(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8-((4-methylpiperazin-1-yl)methyl)-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 15a 
 1-Methylpiperazine (0.48 mmol, 0.050 mL) was added into 
the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using 
the general procedure A, 15a was obtained as colourless solid (37 %, 0.051 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ5.21 (1H, dd, J = 2.2, 12.0, CH=C), 3.80 (1H, t, J = 9.2, 
CHOCO), 2.80 (1H, dd, J = 4.8, 13.6, CHCH2N), 2.75 (2H, dd, J = 5.6, 14.4, 
CHCHCH2), 2.01 to 2.60 (18H, m), 1.80 (1H, s), 1.70 (3H, s, CH3C=CH), 1.55 to 
1.68 (1H, m), 1.28 (3H, s, CH3C), 1.16 to 1.27 (1H, m). 
13
C NMR (100 MHz, CDCl3): 
δ17.1, 24.1, 30.1, 36.7, 41.2, 46.0, 46.3, 48.0, 53.8, 55.2, 56.4, 61.5, 66.7, 82.3, 124.9, 
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134.7, 176.5.; mp=163-164 °C; [α]
18
D =-2° (c =1, CDCl3); IR (neat) cm
-1
 1769 (C=O).; 




(1aR, 7aS, 8R, 10aS, 10bS, E)-1a,5-Dimethyl-8-((prop-2-yn-1-ylamino)methyl)-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 15b 
Propargylamine (0.48 mmol, 0.03 mL) was added into the 
stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the 
general procedure A, 15b was obtained as yellow oil (36 %, 0.044 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ5.32 (1H, dd, J = 2.0, 12.0, CH=C), 3.80 (1H, t, J = 9.2, 
CHOCO), 3.48 (2H, d, J = 2.4, NCH2C), 3.08 (1H, dd, J = 4.8, 13.6, CHCH2N), 2.91 
(2H, dd, J = 5.6, 14.4, CHCHCH2), 2.78 (1H, d, J = 8.8, CHCHCH2), 1.85 to 2.55 
(11H, m), 1.73 (3H, s, CH3C=CH), 1.65 to 1.70 (1H, m), 1.31 (3H, s, CH3C), 1.18 to 
1.28 (1H, m). 
13
C NMR (100 MHz, CDCl3): δ16.9, 17.2, 24.1, 30.0, 36.6, 38.6, 41.1, 
46.1, 46.7, 48.0, 61.5, 66.3, 71.7, 81.7, 82.6, 125.2, 134.4, 176.5.; [α]
18
D =-34° (c =1, 
CDCl3); IR (neat) cm
-1







Glycine (0.48 mmol, 0.022g) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 15ml methanol and water mixture and 
using the general procedure B, 15c was obtained as a colourless crystalline solid 
(28 %, 0.036 g). 
1
H NMR δH (400 MHz, DMSO) δ5.25 (1H, dd, J = 2.0, 12.0, CH=C), 
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3.80 (1H, t, J = 9.2, CHOCO), 2.78 (4H, d, J = 9.2), 1.85 to 2.55 (10H, m), 1.65 (3H, 
s, CH3C=CH), 1.60 to 1.70 (1H, m), 1.20 (3H, s, CH3C), 1.05 to 1.15 (1H, m). 
13
C 
NMR (100 MHz, DMSO): δ16.6, 16.8, 23.7, 28.9, 36.1, 40.5, 45.8, 47.1, 47.6, 55.0, 
61.1, 65.5, 81.5, 124.4, 134.4, 173.1, 176.8.; mp= 164-165 °C; [α]
18
D =-27.6° (c =1, 
D2O); IR (neat) cm
-1







acid: Compound 15d 
L-alanine (0.48 mmol, 0.043g) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 15ml methanol and water mixture and 
using the general procedure B, 15d was obtained as a colourless crystalline solid 
(36 %, 0.046 g).
1
H NMR δH (400 MHz, DMSO) δ5.20 (1H, dd, J = 2.4, 12.0, CH=C), 
4.05 (1H, t, J = 9.1, CHOCO), 3.60 to 3.82 (2H, m), 3.18 to 3.50 (2H, m), 2.85 to 3.17 
(2H, m), 1.90 to 2.80 (6H, m), 1.78 (2H, s), 1.61 (3H, s, CH3C), 1.05 to 1.27 (6H, m). 
13
C NMR (100 MHz, DMSO): δ14.0, 16.6, 16.8, 18.1, 20.7, 23.6, 28.8, 36.1, 45.7, 
46.9, 49.8, 57.4, 59.7, 65.3, 81.8, 124.4, 134.4, 176.7.; mp= 189-191 °C; [α]
18
D =-26.8° 
(c =1, D2O); IR (neat) cm
-1







phenylpropanoic acid: Compound15e 
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L-phenylalanine (0.48 mmol, 0.08g) was added into 
the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 15ml methanol and water 
mixture and using the general procedure B, 15e was obtained as a colourless 
crystalline solid (34 %, 0.056 g). 
1
H NMR δH (400 MHz, DMSO) δ7.25 (5H, m, Ph), 
5.25 (1H, dd, J = 2.0, 12.0, CH=C), 3.90 (1H, t, J = 9.2, CHOCO), 3.40 to 3.48 (2H, 
m), 2.85 to 2.91 (2H, m), 2.81 (1H, dd, J = 4.8, 13.6, CHCH2N), 2.60 to 2.69 (2H, m), 
2.00 to 2.55 (6H, m), 1.90 (1H, t, J = 12, CCH2CH2CH), 1.75 (1H, dd, J = 5.6, 14.8, 
CH3CCH2CH2), 1.60 (3H, s, CH3C=CH), 1.60 to 1.70 (1H, m), 1.20 (3H, s, CH3C), 
1.05 to 1.15 (1H, m). 
13
C NMR (100 MHz, DMSO): δ16.6, 16.8, 23.6, 28.8, 36.1, 
38.6, 38.9, 39.1, 44.8, 45.5, 47.4, 61.0, 62.9, 65.4, 81.6, 124.3, 126.1, 128.0, 129.2, 
134.4, 138.5, 148.0, 175.1, 176.8.; mp= 150-152 °C; [α]
18
D =-14° (c =1, D2O); IR 
(neat) cm
-1







methylbutanoic acid: Compound 15f 
L-valine (0.48 mmol, 0.056g) was added into the stirred 
solution of Parthenolide (100 mg, 0.4 mmol) in 15ml methanol and water mixture and 
using the general procedure B, 15f was obtained as a colourless crystalline solid 
(26 %, 0.038 g). 
1
H NMR δH (400 MHz, D2O) δ7.80 (1H, dd, J = 2.0, 12.0, CH=C), 
6.78 (1H, t, J = 9, CHOCO), 5.85 to 5.95 (1H, m), 5.78 to 5.82 (2H, m), 5.52 to 5.56 
(2H, m), 4.50 to 5.01 (8H, m), 4.29 to 4.33 (2H, m), 4.21 (3H, s, CH3-C=CH), 3.80 
(3H, s, CH3-C), 3.15 to 3.25 (1H, m), 3.45 (6H, dd, J = 6.8, 14 CHCH3).
13
C NMR 
(100 MHz, D2O): δ18.5, 18.6, 19.8, 20.7, 26.0, 30.9, 32.0, 38.0, 38.7, 42.5, 46.0, 48.2, 
49.3, 67.4, 69.2, 71.4, 85.9, 127.3, 138.4, 180.7. mp= 119-120 °C; [α]
18
D =-6.4° (c =1, 
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D2O); IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-8-(((2-Hydroxyethyl)amino)methyl)-1a,5-dimethyl-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 15g 
 Ethanolamine (0.48 mmol, 0.03 mL) was added into the 
stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol and using the 
general procedure A, 15g was obtained as yellow oil (77 %, 0.095 g). 
1
H NMR δH 
(400 MHz, CDCl3) δ5.35 (1H, dd, J = 2.0, 12.0, CH=C), 3.90 (1H, t, J = 9.2, 
CHOCO), 3.65 (2H, t, J = 4.8, CH3OH), 3.00 (1H, dd, J = 4.8, 13.6, CHCH2N), 2.70 
to 2.90 (4H, m), 1.85 to 2.65 (10, m), 1.70 (3H, s, CH3C=CH), 1.65 to 1.75 (1H, m), 
1.30 (3H, s, CH3C), 1.18 to 1.28 (1H, m). 
13
C NMR (100 MHz, CDCl3): δ16.9, 17.2, 
24.1, 29.9, 36.6, 41.1, 46.8, 47.9, 51.4, 60.8, 61.7, 66.3, 82.6, 125.1, 134.5, 177.0.; 
[α]
18
D =-38° (c =1, CDCl3); IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-8-((Ethyl(2-hydroxyethyl)amino)methyl)-1a,5-
dimethyl-2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one: Compound 15h 
 2-(Ethylamino)ethanol (0.48 mmol, 0.047 mL) was 
added into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol 
and using the general procedure A, 15h was obtained as clear oil (21 %, 0.028 g). 
1
H 
NMR δH (400 MHz, CDCl3) δ5.20 (1H, dd, J = 2.0, 12.0, CH=C), 3.85 (1H, t, J = 9, 
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CHOCO), 3.60 (2H, t, J = 5.2, CH2O ), 2.80 (1H, dd, J = 4.8, 13.6, CHCH2N), 2.60 to 
2.75 (5H, m), 2.00 to 2.45 (10, m), 1.70 (3H, s, CH3C=CH), 1.65 to 1.75 (1H, m), 
1.30 (3H, s, CH3C), 1.18 to 1.28 (1H, m), 1.06 (3H, t, J = 7.2, CH3CH2N). 
13
C NMR 
(100 MHz, CDCl3): δ11.4, 16.9, 17.2, 23.1, 24.1, 30.0, 36.6, 41.1, 46.5, 47.7, 48.2, 
52.4, 55.4, 58.9, 61.5, 66.4, 82.1, 125.3, 134.3, 176.5.; [α]
18
D =-26° (c =1, CDCl3); IR 
(neat) cm
-1




(1aR, 7aS, 8R, 10aS, 10bS, E)-8-(((2-Methoxyethyl)amino)methyl)-1a,5-dimethyl-
2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-9(1aH)-
one: Compound 15i 
2-Methyoxyethylamine (0.48 mmol, 0.047 mL) was 
added into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL methanol 
and using the general procedure A, 15i was obtained as yellow solid (57 %, 0.074 g). 
1
H NMR δH (400 MHz, CDCl3) δ5.18 (1H, dd, J = 2.0, 12.0, CH=C), 3.85 (1H, t, J = 
9, CHOCO), 3.50 (2H, t, J = 5.2, CH2O ), 3.35 (3H, t, OCH3), 3.00 (1H, dd, J = 4.8, 
13.6, CHCH2N), 2.70 to 2.90 (4H, m), 2.05 to 2.50 (8H, m), 1.95 (1H, dd, J = 6, 14.8, 
CH2CH2CO), 1.70 (3H, s, CH3C=CH), 1.65 to 1.75 (1H, m), 1.30 (3H, s, CH3C), 1.15 
to 1.25 (1H, m).
13
C NMR (100 MHz, CDCl3): δ16.9, 17.2, 24.1, 30.0, 36.6, 41.1, 46.7, 
46.8, 47.4, 47.9, 49.5, 58.8, 61.5, 66.3, 72.0, 82.5, 125.1, 134.5, 176.7.;mp=105-
107 °C; [α]
18
D =-49.6° (c =1, CDCl3); IR (neat) cm
-1





(1aR, 7aS, 8R, 10aS, 10bS, E)-8-(((2-Methoxyethyl)(methyl)amino)methyl)-1a,5-
dimethyl-2,3,6,7,7a,8,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-
9(1aH)-one: Compound 15j 
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(2-Methoxyethyl)methylamine (0.48 mmol, 0.052 mL) 
was added into the stirred solution of Parthenolide (100 mg, 0.4 mmol) in 10 mL 
methanol and using the general procedure A, 15j was obtained as yellow semi-solid 
(13 %, 0.02 g). 
1
H NMR δH (400 MHz, CDCl3) δ5.20 (1H, dd, J = 2.0, 12.0, CH=C), 
3.80 (1H, t, J = 9, CHOCO), 3.50 (2H, t, J = 5.2, CH2O), 3.35 (3H, t, OCH3), 2.85 
(1H, dd, J = 4.8, 13.6, CHCH2N), 2.70 to 2.80 (2H, m), 2.65 (2H, t, J = 5.6, 
CH2CH2N), 2.00 to 2.45 (11H, m), 1.70 (3H, s, CH3C=CH), 1.65 to 1.75 (1H, m), 
1.30 (3H, s, CH3C), 1.15 to 1.25 (1H, m). 
13
C NMR (100 MHz, CDCl3): δ17.0, 17.2, 
24.1, 29.7, 29.9, 36.7, 41.0, 43.5, 46.7, 47.6, 56.1, 57.7, 58.8, 61.5, 66.5, 71.0, 82.2, 
124.9, 134.7, 176.7.; [α]
18
D =-10° (c =1, CDCl3); IR (neat) cm
-1
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